CONFIDENTIAL  GeoVax, Inc.  
Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
Phase 1/2, Open- label Study Evaluating the Safety of  
Repeat Administration of Ad/PNP -F-araAMP  (Ad/PNP 
Administered Intratumorally with Co -administration of 
Fludarabine Phosphate Intravenously) in Subjects with Recurrent, 
Local Head and Neck Cancer  
Protocol No. PNP -[ADDRESS_1136188] 
Smyrna, GA [ZIP_CODE]  
Phone : ([PHONE_17128]  
Fax: ([PHONE_17129] 
 www.geovax.com  
Sp
onsor Contact:  
[INVESTIGATOR_204994] T. McKee, Jr., MD, MPH  
Email: [EMAIL_15583]  
Contract Research Organization:  
CATO SMS, Ltd.  
[ADDRESS_1136189]  
Cary, NC [ZIP_CODE] Coordinating Investigator : 
A. Dimitrios Colevas, M.D.
Phone: (650) 724- 9707
Fax: ([PHONE_17130] 
Email: [EMAIL_10891]  

CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 2 Document  History  
Amendment Date  Notes  
Version  1 Date: July  [ADDRESS_1136190] (IRB)  
Version 2 Date: 8.7.2017  Initial IRB/SRC Submission  
Version 2 Date: 10.6.2017  SRC Edits  
Version 2 Date: 11.16.2017  SRC Pre -Comments  
Version 02 Date: 05 September 2018  Clarify enrollment numbers; adverse event (AE)  reporting criteria and  
instructions  
Version 03 Date: 28 February 2019  Revision includes:  
- Removal of requirement for emergency equipment beyond usual 
resources  
Version 04 Dat e: 06 May 2022 
 Revision includes:  
- Addition of “Statement of Compliance”, “Sponsor’s Approval”, and 
“Investigator’s Agreement” sections  
- Coordinating center changed to GeoVax, Inc. and study changed to a multisite study with accompanying edits to the Safety Monitoring 
Committee Charter and sections in the protocol regarding the Safety 
Monitoring Committee  
- Clarification of Inclusion/Exclusion Criteria: patients with 
histologically or cytologically confirmed diagnosis of recurrent 
cancer of the head and neck region for whom there is no curative 
treatment option; for the purposes of trial eligibility, head and neck 
cancer shall  include, in addition to head and neck squamous cell 
carcinoma (HNSCC) , cutaneous squamous cell primary sites and 
squamous cell carcinoma of unknown primary presenting with neck lymph nodal disease, as well as nasopharyngeal carcinoma, and 
salivary gland tumors ; patients with resolved side effects can receive 
treatment earlier than [ADDRESS_1136191] chemotherapy dose  
- Removal of Section 2.6 Correlative Studies Background since there were no correlative studies 
- Removal of “Description of Study Drug” S ection 4.1 since this text 
was referenced  in “Description of Study Drug” Section 5.1. 
- Edits to study calendar: extension of screening period window; 
adjustments to pharmacokinetic  collection and vitals timepoints , 
removal of projected study completion  timelines;   
- Moved the first paragraph describing how tumor response will be 
assessed from Section 12.[ADDRESS_1136192] Research 
Organization (CRO)  in Section 11.9 Study Monitoring and Auditing  
- Clarification of endpoints  and alignment of terminology with F ood 
and Drug Administration (FDA) guidance and industry standards   
- Clarification of the Statistical Consideration section  and added a 
description of study power 
- Minor grammatical and typographical updates throughout to 
improve clarity and readability  
- Miscellaneous edits to promote consistency  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 3 STATEMENT OF COMPLIANCE  
The study will be conducted in compliance with this clinical study protocol, Good Clinical 
Practices (GCP) as outlined by [CONTACT_819965] (ICH) E6(R2), and all 
applicable local and national regulatory requirements. Enrollment at any clinical study site may not begin prior to that site receiving approval from the ethics committee of record for the protocol and all materials provided to potential participants.  
Any amendments to the protocol or changes to the consent document will be approved before implementation of that amendment. Reconsent of previously enrolled participants may be necessary depending on the nature of the amendment. 
The Principal Investigator [INVESTIGATOR_261819], unless such a change is necessary to el iminate an immediate hazard to 
the study participants. 
All personnel involved in the conduct of this study have completed Human Subjects Protection 
and GCP Training as outlined by [CONTACT_34636].  
  
CONFIDENTIAL GeoVax, Inc.
Ad/PNP-F-araAMP
Protocol No. PNP-002 V4.0 06 May 2022
Page 4Title Phase 1/2, Open-label Study Evaluating the Safety of Repeat Administration of Ad/PNP-F-
araAMP (Ad/PNP Administered Intratumorally with Co-administration of Fludarabine 
Phosphate Intravenously) in Subjects with Recurrent, Local Head and Neck CancerProtocol Number PNP-002
Version Number 04
Version Date 06 May 2022
responsible personnel as indicated in the signature [CONTACT_34702].
Medical Representative
Name: [CONTACT_1641]: Signature: [CONTACT_1782]:
Kelly McKee, MD, MPH Chief Medical Officer 
Coordinating Investigator 
[CONTACT_5627]: Title: Signature: [CONTACT_1782]:
A. Dimitrios Colevas, MD Professor of Medicine,
Stanford University

CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
 
 Page 5 INVESTIGATOR’S AGREEMENT  
I have read the protocol, appendices, and accessory materials related to Study [insert number] and 
agree to the following: 
• To conduct this study as described by [CONTACT_34638]  
• To protect the rights, safety, and welfare of the participants under my care  
• To provide oversight to all personnel to whom study activities have been delegated  
• To control all investigational products provided by [CONTACT_819966]  
• To conduct the study in accordance with all applicable local and national regulations, the requirements of the ethics committee of record for my clinical site, and Good Clinical Practices as outlined by [CONTACT_12212] E6(R2). 
• To obtain approval for the protocol and all written materials provided to participants prior to initiating the study at my site  
• To obtain informed consent – and updated consent in the event of new information or 
amendments – from all participants enrolled at my study site prior to initiating any 
study‑specific procedures or administering investigational products to those participants  
• To maintain records of each subject’s participation and all data required by [CONTACT_819967]  
[Insert last name, first name]  
 [Insert title (at institution)]  [Insert address]  
 
 
Signature  [CONTACT_1782] 
 
 
 [DD Month YYYY]  
 
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 6 TABLE OF CONTENTS  
 
Page  
 
STATEMENT OF COMPLIANCE  .............................................................................................................................. 3  
SPONSOR’S APPROVAL  ............................................................................................................................................ 4  
INVESTIGATOR’S AGREEMENT  ............................................................................................................................. [ADDRESS_1136193] OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................................................................ 14 
1. OBJECTIVES .............................................................................................................................................. 16 
1.1 Primary  Objective  ......................................................................................................................................... 16 
1.2 Secondary Objectives  .................................................................................................................................... 16 
2. BACKGROUND  .......................................................................................................................................... 17 
2.1 Advanced Head and Neck  Cancer  ................................................................................................................. 17 
2.2 Description of Ad/PNP -F-araAMP  ............................................................................................................... 18 
2.3 Tumor Response with Ad/PNP -F-araAMP in Phase [ADDRESS_1136194] Withdrawal ....................................................................................................................................... 23 
4. TREATMENT PLAN  ................................................................................................................................. 25 
4.1 Dose and Dose Rationale  .............................................................................................................................. 25 
4.2 Administration of Ad/PNP-F- araAMP per Cycle.......................................................................................... 25 
4.3 Dose Modification  ......................................................................................................................................... 27 
4.4 Expected Adverse Events  .............................................................................................................................. 28 
4.4.1  Infection  Prophylaxis  .................................................................................................................... 29 
4.5 Stoppi[INVESTIGATOR_1869]  .............................................................................................................................................. 29 
4.6 Drug Accountability  ...................................................................................................................................... 30 
4.7 Concomitant Medications  .............................................................................................................................. 30 
4.8 Criteria for Removal from Study  ................................................................................................................... 31 
5. INVESTIGATIONAL AGENT/DEVICE/PROCEDURE INFORMATION  ........................................ 32 
5.1 Description of Study Drug  ............................................................................................................................ 32 
5.2 Availability  .................................................................................................................................................... 32 
5.3 Agent Ordering  .............................................................................................................................................. 33 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
TABLE OF CONTENTS (continued)  
 
Page  
 
 
 Page 7 5.4 Agent Accountability  .................................................................................................................................... 33 
6. DOSE MODIFICATIONS  .......................................................................................................................... 34 
7. ADVERSE EVENTS AND REPORTING PROCEDURES  .................................................................... 35 
7.1 Adverse  Event  ............................................................................................................................................... 35 
7.2 Serious Adverse Event  .................................................................................................................................. 35 
7.3 Assessment of Causality  ................................................................................................................................ 36 
7.4 Severity of the Adverse Event  ....................................................................................................................... 37 
7.5 Safety Monitoring and Reporting  .................................................................................................................. 37 
7.5.1  Monitoring of Adverse  Events  ...................................................................................................... 37 
7.5.2  Recording and Reporting Adverse Events and Serious Adverse Events  ...................................... 38 
7.5.3  Safety Monitoring Committee  ...................................................................................................... 39 
8. CORRELATIVE/SPECIAL STUDIES  ..................................................................................................... 40 
9. STUDY CALENDAR  .................................................................................................................................. 43 
9.1 Study Procedures Table  ................................................................................................................................. 43 
9.2 Study Procedures  ........................................................................................................................................... 45 
9.2.1  Visit 1 (Day - 30 to 0, Screening and Baseline Laboratory Values)  .............................................. 45 
9.2.2  Visits 2 and 3 (Days 1 and 2 of Intratumoral Administration of Ad/PNP)  ................................... 46 
9.2.3  Visit 4 (Day 3, First infusion of F -araAMP)  ................................................................................. 47 
9.2.4  Visits 5 and 6 (Days 4 and 5)  ........................................................................................................ 48 
9.2.5  Visit 7 (Days 14 ± 2) ..................................................................................................................... 48 
9.2.6  Visit 8 (Day 28 ± [ADDRESS_1136195] Cycle)  .......................................................................................... 49 
9.2.7  Visit 9 or Termination Visit (Day 56 ± [ADDRESS_1136196] Cycle)  ........................................................ 49 
9.3 Description of Evaluations  ............................................................................................................................ 50 
9.3.1  Laboratory Evaluations  ................................................................................................................. 50 
9.3.2  Physical Examination  ................................................................................................................... 50 
9.3.3  Medical History  ............................................................................................................................ 51 
9.3.4  Tumor Response  ........................................................................................................................... 51 
9.3.5  Radiographic Imaging  .................................................................................................................. 52 
9.4 Tumor Biopsies  ............................................................................................................................................. 52 
10. MEASUREMENTS  ..................................................................................................................................... 53 
10.1 Primary Outcome Measure  ............................................................................................................................ 53 
10.2 Secondary Outcome Measure  ........................................................................................................................ 53 
10.3 Primary and Secondary Outcome Measures -Discussion:  .............................................................................. 53 
10.3.1  Relevant Subset  ............................................................................................................................ 54 
10.3.2  Measurement Definition  ............................................................................................................... 54 
10.3.3  Measurement Methods  .................................................................................................................. 55 
10.3.4  Measurement Time Points  ............................................................................................................ 55 
10.3.5  Response Review  .......................................................................................................................... 55 
11. REGULATORY CONSIDERATIONS  ..................................................................................................... 56 
11.1 Institutional Review of Protocol  .................................................................................................................... 56 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
TABLE OF CONTENTS (continued)  
 
Page  
 
 
 Page [ADDRESS_1136197] Confidentiality  .................................................................................................................................. 57 
11.5 Adherence to Reporting Requirements  ......................................................................................................... 58 
11.6 Records  .......................................................................................................................................................... 58 
11.7 Protocol Approval and Amendments  ............................................................................................................ 59 
11.8 Closure of the Study  ...................................................................................................................................... 59 
11.9 Study Monitoring and Auditing .................................................................................................................... 60 
11.10  Documentation of Study Findings  ................................................................................................................. 60 
12. STATISTICAL CONSIDERATIONS  ....................................................................................................... 61 
12.1 Sample Size ................................................................................................................................................... 61 
12.2 Assessment of Safety Measures  .................................................................................................................... 62 
12.3 Adverse Events  .............................................................................................................................................. 62 
12.4 Clinical Laboratory Results  ........................................................................................................................... 62 
12.5 Vital Signs and Physical Examination  .......................................................................................................... 63 
12.6 Assessment of Efficacy Measures  ................................................................................................................. 63 
13. REFERENCES  ............................................................................................................................................ 65 
APPENDICES  ............................................................................................................................................................. 66 
   
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 9 PROTOCOL SYNOPSIS  
Title  
Phase 1/2, Open- label Study Evaluating the Safety of Repeat Administration of Ad/PNP -F-
araAMP  (Ad/PNP Administered Intratumorally with Co -administration of Fludarabine 
Phosphate Intravenously) in Subjects with Recurrent, Local Head and Neck Cancer 
Study Objectives  
The primary objective of the study is to evaluate the safety of repeat administration of a dose 
level of Ad/PNP -F-araAMP that demonstrated anti -tumor activity in patients with advanced head 
and neck cancer in the completed Phase 1 study. 
 
The secondary objective of the study is to evaluate the anti -tumor activity of repeat 
administration of Ad/PNP -F-araAMP.  
Study Design  
The study is an open- label , multisite , Phase 1/2 study  evaluating  the safety  and anti-tumor activity 
of Ad/PNP -F-araAMP in subjects with recurrent cancer of the head and neck region who have 
relapsed following curative treatment and without additional potentially curative treatment 
options. The study is designed to evaluate repeat administration (up to 5 cycles) of a single dose 
level of Ad/PNP administered intratumorally followed by [CONTACT_33980] (IV) F-araAMP.  
Sample Size and Duration of Study  
It is anticipated that approximately [ADDRESS_1136198] will be followed for ~ [ADDRESS_1136199] dose of study medication. Based on the patient population, it is anticipated that the study 
will require 36 to 48 months to be completed. 
Study Population  
Inclusion Criteria  
1. Provided Informed Consent 
2. Age ≥ 18 years  
3. Patients with histologically or cytologically confirmed diagnosis of recurrent cancer of the 
head and neck region for whom there is no curative treatment option. For the purposes of 
trial eligibility, cancers of the head and neck shall  include, in addition to head and neck 
squamous cell carcinoma (HNSCC) , cutaneous squamous cell primary sites and squamous 
cell carcinoma of unknown primary presenting with neck lymph nodal disease, as well as 
nasopharyngeal carcinoma, and salivary gland tumors. 
4. All standard or approved treatment options that would provide substantive palliation must 
have failed, been exhausted, or patient not eligible for them (for example neuropathy, 
nephropathy, or hearing loss precluding the use of cisplatin). 
5. Tumor mass (primary tumor and/or lymphadenopathy) measurable by R esponse Evaluation 
Criteria in Solid Tumors (RECIST)  1.1 and technically suitable for  intratumoral injections 
(otolaryngologist will determine feasibility). Patients with nodal disease (or metastatic 
disease) that is needle accessible are eligible. Patients with  additional tumors (including 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
PROTOCOL SYNOPSIS  (continued)  
 
 
 
 Page 10 distant metastatic disease) beyond the intratumoral injection accessible tumor(s) that are not 
accessible for intratumoral injection are eligible ONLY if the patient has no other treatment 
option for the metastatic disease and treatment of local disease ma y provide the patient 
some benefit or palliation.  
6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤  2. 
7. In the judgment of the Investigator, the patient has recovered sufficiently from any previous 
significant therapy side effects or toxicities prior to Ad/PNP administration.  
8. Absolute neutrophil count [ANC] ≥ 1,500 cells/µl; hemoglobin ≥ 9 g/dl, platelets ≥  
100,000/µl . 
9. Serum creatinine ≤ 1.5 mg/dl, or calculated creatinine clearance ≥ 60 ml/min . 
10. Bilirubin ≤ upper limit normal [ULN], alanine aminotransferase [ALT] ≤ 1.[ADDRESS_1136200] and/or 
aspartate aminotransferase [AST] ≤ 1.[ADDRESS_1136201], alkaline phosphatase  ≤ 2.[ADDRESS_1136202] . 
11. Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.[ADDRESS_1136203]. 
12. Activated partial thromboplastin (aPTT) time ≤ 1.[ADDRESS_1136204] a negative urine or serum pregnancy at screening (pregnancy 
test is not required for patients with bilateral oophorectomy and/or hysterectomy or for 
those patients who are > 1 year  postmenopausal). 
14. All patients of reproductive potential must agree to use a medically acceptable  form of 
contraception (e.g., hormonal birth control, double-barrier method) or abstinence.  
 
Exclusion Criteria  
1. Prior history or current diagnosis of leukemia . 
2. Have received any gene therapy products or oncolytic viral therapy . 
3. Receiving  allopurinol. 
4. Received an investigational drug within [ADDRESS_1136205] injection of Ad/PNP . 
5. Received radiation treatment < [ADDRESS_1136206] injection of Ad/PNP and does not have 
any RECIST 1.1 evaluable lesions that are outside the radiation field. (If the patient has 
RECIST 1.1 evaluable lesions outside the radiation field then they can be included.) 
6. Received chemotherapy (systemic anticancer treatment) < [ADDRESS_1136207] injection 
of Ad/PNP and has not recovered from all the related side effects. (If the patient has 
recovered from all related side effects or has reached a new baseline, then they may begin  
receiving treatment at sooner than 4 weeks). 
7. Have significant baseline neuropathy (> G rade 2 based on Common Terminology Criteria 
for Adverse events [ CTCAE ] v5.0). 
8. Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease, active  
infection). 
9. Had within 6 months prior to enrollment: myocardial infarction ( MI), cerebral vascular 
accident ( CVA) , uncontrolled congestive heart failure ( CHF ), significant liver disease, 
unstable angina. 
10. Fever (temperature > 38.1 °C orally) . 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
PROTOCOL SYNOPSIS  (continued)  
 
 
 
 Page 11 11. Receiving chronic systemic corticosteroids (> 3 weeks) or any chronic immunosuppressive 
medications within [ADDRESS_1136208] injection of  Ad/PNP.  Subjects receiving short 
courses of corticosteroids are considered eligible for the study. 
12. Receiving anticoagulants other than those to maintain patency of venous lines. 
13. Women who are pregnant or breast feeding 
14. Known history of human immunodeficiency virus (HIV) infection. No requirement for 
testing.  
 
Study Drug and Administration  
• 2 x 1011 viral particle (VP) x 3 over 2 days per cycle (total up to: 3 x 1012 Ad/PNP over 5 
cycles) intratumorally, followed  by: 
• 25 mg/m2 F-araAMP daily x 3 days (total: 75 mg/m2 per cycle) intravenously, over 
approximately 30 minutes  
Endpoints  
The primary endpoint is safety with repeat cycles of treatment. Safety measures include adverse 
events (AE) and laboratory parameters.  
 
Anti-tumor response will also be assessed  for injected tumors and overall as determined by  
[CONTACT_393] v.1.1. Efficacy assessments include:  
• Objective response rate (ORR) , defined as the percentage of patients with a best overall 
response (BOR) of a complete response ( CR) or a partial response  (PR). BOR is the best 
response achieved during the [ADDRESS_1136209] v.1.1.  
• Durable response rate defined as a BOR of CR or PR  for injected tumors and overall as 
determined  by [CONTACT_393] v.1.[ADDRESS_1136210] 4 weeks . 
• Time to response (TTR)  defined as time from first intratumoral injection to date of first  
response value of CR or PR  for injected tumors and overall as determined by [CONTACT_393] v.1.1.  
• Overall survival  (OS) defined as time from first intratumoral injection to date of progression 
or death  for any cause , whichever occurs first.  
• Progression free survival (PFS) defined as time from first intratumoral injection to date of 
progression or death for any cause, whichever occurs first.  
• Duration of response  (DOR) defined as time from first documentation of CR or PR for 
injected tumors  and overall as determined by [CONTACT_393] v.1.[ADDRESS_1136211]  as applied here will be version 1.1. Efficacy will be assessed in the population of 
subjects who receive three intratumoral administrations of Ad/PNP and any infusion of 
F-araAMP.  
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06  May 2022  
 
PROTOCOL SYNOPSIS  (continued)  
 
 
 
 Page 12 Statistical Methods  
The study is a Phase 1/2  safety study; no formal hypotheses or sample size estimates will be  
generated.  The study will enroll 10 to 20 subjects to achieve 10 subjects evaluable for efficacy;  
this number of subjects is sufficient to assess preliminary safety and activity to guide design of 
subsequent clinical studies.  
 
A total of 10 to 20 subjects in the safety population provides sufficient precision to rule out a 
treatment -related serious adverse event (SAE)  rate of 38.5% or more using a one -sided 80% 
upper confidence limit. With 10 subjects evaluable for efficacy, there is 83% power to reject a 
null hypothesis ORR of 10% or less when the alternative hypothesis ORR is at least 40% using 
a one- sided exact binomial test with a target alpha level of 10% (actual alpha is 7%) . 
 
Descriptive statistics ( number and percentage of subjects ) will be used to summarize  BOR , ORR, 
and durable response rate . 95% Clopper -Pearson confidence intervals will also be provided. OS, 
PFS, DOR , and TTR will be analyzed based on Kaplan -Meier methods; Kaplan -Meier curves 
will be plotted over time. The number and percentage of subjects identified to have had an event 
and those who were censored will be displayed. The median time to event and its corresponding 
95% CI will also be produced . A listing of response for subjects will be provided.  
Duration of Study Participation  
Each subject will participate for approximately 180 days. 
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 13  
SCHEMA  
 
DLT = Dose -limiting toxicity; IV = intravenously; PD = progressive disease, VP = viral particle;  

CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136212] overall response  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
CBER  Center for Biologics Evaluation and Research (of the FDA)  
CFR  Code of Federal Regulations  
CHF  Congestive heart failure  
CLL  Chronic lymphocytic leukemia  
Cr Creatinine  
CR Complete response  
CRF  Case report form  
CRT  Chemoradiation treatment  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CVA  Cerebral vascular accident  
CXR  Chest X -ray 
dL Decaliter  
DLT  Dose -limiting toxicity  
DNA  Deoxyribonucleic acid  
DOR  Duration of response  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
F-Ade Fluoroadenine  
F-araA  Fludarabine  
F-araAMP  Fludarabine phosphate  
(F-) ATP  (2-F-) adenosine triphosphate  
5-FU 5-fluorouracil  
FDA  Food and Drug Administration  
G-CSF Granulocyte colony -stimulating factor  
GCP  Good clinical practice  
GM-CSF Granulocyte -macrophage colony -stimulating factor  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
HNSCC  Head and neck squamous cell carcinoma  
HPLC  High performance liquid chromatography  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
IV Intravenous (ly) 
kg Kilogram  
LC/MS  Liquid chromatography/mass spectrometry  
LD Longest diameter  
mg Milligram  
MI Myocardial infarction  
mL Milliliter  
MRI  Magnetic resonance imaging  
NCI National Cancer Institute  
NOAEL  No-observable -adverse effect -level  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136213] OF ABBREVIATIONS AND DEFINITION OF TERMS  (continued)  
 
 Page 15 OBA/NIH  Office of Biotechnology Activities/National Institutes of  Health  
ORR  Objective  response  rate 
OS Overall survival  
PD Progressive disease  
PFS Progression free survival  
PI [INVESTIGATOR_819948]  
R/M Recurrent and/or metastatic  
RNA  Ribonucleic acid  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE  Serious adverse event  
SD Stable disease  
SMC  Safety Monitoring Committee  
SMX  Sulfamethoxazole  
TEAE  Treatment -emergent adverse event  
TMP  Trimethoprim  
TTR  Time to response  
ULN  Upper limit of normal  
VP Viral particle  
µl Microliter  
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 16 1. OBJECTIVES  
1.1 Primary  Objective  
The primary  objective of the study is to evaluate the safety  of repeat  administration  of a dose level 
of Ad/PNP -F-araAMP that demonstrated anti -tumor activity in patients with advanced head an d 
neck cancer in the completed Phase 1  study. 
1.2 Secondary Objectives  
The secondary objective is to evaluate the anti -tumor activity of repeat administration of Ad/PNP - 
F-araAMP . 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 17 2. BACKGROUND 
2.1 Advanced Head and Neck Cancer  
More than half of patients with head and neck squamous cell carcinoma (HNSCC) have 
locoregionally advanced  cancer  and approximately 10% have metastatic  disease at the time of their 
initial diagnosis. Patients with resectable disease who receive adjuvant chemoradiation treatment 
(CRT ) following surgery have a 5 -year recurrence rate of 20%. Although some patients with 
recurrent disease can be salvaged with surgery or radiation therapy, the majority are incurable and 
are treated palliatively with systemic therapy. Patients with recurrent and/or metastatic (R/M) 
HNSCC receiving first - line chemotherapy for recurrent disease have a median overall survival 
(OS) of ~7 months. The prognosis for patients with R/M HNSCC when first -line chemotherapy 
fails for recurrent disease is dismal, with median OS of < 6 months [1]. 
The most common non- targeted, first -line treatment approach for R/M HNSCC in patients who  
are not candidates for surgery or radiation treatment is a platinum -containing agent (cisplatin, 
carboplatin) combined with either 5-fluorouracil (5- FU) or taxane (paclitaxel, docetaxel). 
Response rates and OS in HNSCC following platinum -based dual agent chemotherapy are low,  
i.e., response rates are about 20- 30% and median OS between 6.5 and 8.0 months, across several 
studies [2]. Addition of cetuximab improves response marginally; in a Phase 3 study of R/M 
HNSCC  patients  receiving  platinum- based  chemotherapy  and 5-FU, the median  OS was prolonged 
from 7.4 months with chemotherapy alone to 10.1 months with addition of cetuximab. Median 
progression free survival (PFS) was also increased from 3.3 months to 5.6 months [3]. It should 
be noted that subjects in the study were in good general condition and had good organ function. 
However, not all patients are able to tolerate the intensive triple -drug chemotherapy regimen and 
are offered alternative therapi[INVESTIGATOR_014], e.g., dual therapy with platinum + taxane followed by 
[CONTACT_819968] [4]. 
There are limited treatment options for patients with R/M HNSCC whose tumor fails to respond 
or recurs following first -line salvage treatment. Often, treatment of these patients is limited to 
therapy with non- cross -resistant agents such as cetuximab, methotrexate, nivolumab, or a taxane 
with an overall response rate reported to be less than 20%. Treatment options are further limited 
by [CONTACT_819969]. Therefore, patients with recurrent HNSCC for 
whom platinum -based treatments and cetuximab treatments fail represent a population in need of 
novel therapeutic approaches. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 18 2.2 Description of Ad/PNP -F-araAMP  
The study drug, Ad/PNP -F-araAMP  consists of a non- replicating adenoviral vector expressing the  
Escherichia . coli purine nucleoside phosphorylase (PNP) injected intratumorally followed by 
[CONTACT_33980] (IV) administration of F -araAMP. This combination generates fluoroadenine ( F-Ade) 
within the tumor resulting in focal chemotherapeutic activity.  
F-araAMP is an agent that is rapi[INVESTIGATOR_819949], which is the 
primary circulating form of the drug and has activity against certain hematological malignancies, 
but not against solid tumors such as HNSCC. F -araA is an aden osine analog and substrate for 
E. coli PNP, which cleaves the glycosidic bond of F -araA to generate F -Ade. The F -Ade 
metabolite has shown pronounced activity against human tumor xenografts in mice. 
F-Ade is converted to 2-F- adenosine triphosphate (F -ATP), which interferes with enzymatic 
reactions involving ATP and rapi[INVESTIGATOR_819950]. F -Ade has been shown to inhibit RNA 
and protein synthesis, two functions important to cellular metabolism r egardless of the 
proliferative state of the cell (dividing versus quiescent). In contrast to toxins produced by [CONTACT_819970] 5- FU, F-Ade 
impairs one or more enzymes unrelated to DNA s ynthesis and kills tumor cells that are not actively 
proliferating. Many refractory tumors are refractory precisely because they have a very low growth 
fraction, i.e., a relatively small percentage of tumor cells dividing  at any particular  point in time.  In 
nonclinical studies, significant in vivo anti-tumor activity has been demonstrated by F -Ade 
generation from F -araAMP in tumors in which 2.5 to 10% of cells express the E. coli PNP gene. 
In addition, anti -tumor effect was seen in patients with advanced  solid  tumors (melanoma  and head  
and neck  cancer)  in the higher dose cohorts in a Phase 1  study. 
2.3 Tumor Response with Ad/PNP -F-araAMP in Phase 1  Study  
The safety and efficacy of Ad/PNP -F-araAMP has been evaluated in a Phase 1 study, PNP -001. 
Four escalating  dose levels  were evaluated  in 10 subjects  with head  and neck  cancer  and 2 subjects 
with melanoma; clinical activity was observed at the highest dose levels following 3 IT injections 
of Ad/PNP over 2 days and IV F -araAMP phosphate over 3 days [5]. The overall response rate 
(complete response [ CR] + partial response [ PR]) was 66.7% in the [ADDRESS_1136214] dose cohorts, Cohorts 
3 and 4, versus 33.3% in Cohort 1, and 0% in Cohort 2; these results suggest a dose response effect. The duration of response (DOR) in the injected tumor was limited, with 4 of 5 responding 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136215] follow -up on Day 56, 
suggesting that repeat administration should be evaluated.  
Ad/PNP + F -araAMP was well tolerated. No subject experienced a dose- limiting toxicity (DLT) 
and none of the subjects discontinued study treatment. There was no evidence for an increased 
incidence of treatment -emergent adverse events ( TEAEs ), treatment -related adverse events ( AEs), 
serious adverse events ( SAEs ), or Grade [ADDRESS_1136216] frequently 
reported TEAEs were those associated with the intratumoral injection site, primarily injection site pain (91.7%). The incidence of these  events did not increase with dose, and most were mild or 
moderate in intensity. However, the single subject who experienced the most significant injection 
site pain (Grade 3, requiring subsequent pretreatment with local anesthetic) was in Cohort 4. Pain 
with subsequent Ad/PNP injection in this subject was managed with local lidocaine pre -injection 
and did not lead to discontinuation of study treatment. 
Overall,  the activity  and safety  profile  of Ad/PNP  seen in the Phase 1 study supports further clinical 
evaluation  of repeat  administration  of Ad/PNP  (intratumorally ) and F-araAMP  phosphate infusion 
for patients with recurrent cancer of the head and neck region . 
2.[ADDRESS_1136217] dose levels  of 
Ad/PNP -F-araAMP  in the Phase 1 study, GeoVax  plans to investigate  the safety  and assess 
anti-tumor activity of repeat cycles of injection of Ad/PNP + F -araAMP in patients with advanced 
head and neck  cancer.  The 2 x 10
11 viral particle (V P)/injection  was selected  since there was no 
difference in tumor activity between the 1011 and 1012 VP dose levels in Phase 1 testing, and since 
the total cumulative dose (3.0 x 1012 VP) will be equivalent to the dose of Ad/PNP  that was well 
tolerated  in Cohort 4 of the Phase 1 trial (3  x 1012 VP). Subjects  in the study  will have Response 
Evaluation Criteria in Solid Tumors (RECIST)  1.1 measurable recurrent cancer of the head and neck 
region which is amenable to local injection for which there is no curative treatment option. This 
study population was selected since results from this Phase 1/2  trial are intended to support the 
safety of repeat dosing in further clinical investigations. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 20 2.5 Study  Design  
The trial is designed as a single -arm study to evaluate the safety of repeat cycles of Ad/PNP and 
F-araAMP in patients with recurrent  cancer of the head and neck region with tumor(s) accessible 
for injection. 
Ad/PNP  will be injected  intratumorally  twice  on Day  1 and once on Day 2 followed by 25 mg/m2 
per infusion F -araAMP  daily on Days 3, 4, and 5 infused over approximately 30 minutes. The 
25 mg/m2 F- araAMP dose level is the same as that evaluated in the two highest cohorts in the 
Phase 1 study. Subjects  will receive repeat  administration  of Ad/PNP -F-araAMP  every  4 weeks  
(i.e., each cycle) for 5 cycles or until injected tumor progresses, unacceptable toxicity occurs, no 
tumor is present for injection, or patient death.  
Tumor response in the injected tumor(s) will be assessed by [CONTACT_5292] (tumor 
measurement using ruler or calipers, if tumor can be assessed by [CONTACT_23302]) as well as by 
[CONTACT_128656] ( magnetic resonance imaging [ MRI ] or computed tomography [ CT] scan). 
The same methods to assess the injected tumor(s) will be used at baseline and subsequent time 
points. 
Subjects  will be assessed  for safety  frequently, including D ay [ADDRESS_1136218] or fifth cycle. During the study, subjects will be 
monitored for AEs  including signs of infection, and changes in hematological or chemistry 
parameters (see Study Procedures Table ). 
The Safety Monitoring Committee ( SMC ) will review accumulating  safety data (i.e. , AE reporting, 
reactions to study drug, deaths , etc.) at time intervals  specified in the SMC Charter  and at any other 
time when it is determined by [CONTACT_819971] a review is warranted .  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136219] fulfill the following eligibility criteria.  
3.1 Inclusion Criteria  
1. Provided Informed Consent 
2. Age ≥ [ADDRESS_1136220] failed, been exhausted, or patient not eligible for them (for example neuropathy, 
nephropathy, or hearing loss precluding the use of cisplatin)  
5. Tumor mass (primary tumor and/or lymphadenopathy) measurable by [CONTACT_393] 1.1 and 
technically suitable for intratumoral injections (otolaryngologist will determine feasibility). 
Patients with nodal disease (or metastatic disease) that is needle accessible are eligible. 
Patients with additional tumors (including distant metastatic disease) beyond the intratumoral  
injection accessible tumor(s) that are not accessible for intratumoral injection are eligible 
ONLY if the patient has no other treatment option for the metastatic disease and treatment of local disease may provide the patient some benefit or  palliation.  
6. Eastern Cooperative Oncology Group ( ECOG) performance status of ≤  2. 
7. In the judgment of the i nvestigator, the patient has recovered sufficiently from any previous 
significant therapy side effects or toxicities prior to Ad/PNP administration.  
8. Absolute neutrophil count [ANC] ≥ 1,500 cells/ µl; hemoglobin ≥ 9 g/dl, platelets  ≥ 100,000/µl. 
9. Serum creatinine ≤ 1.5 mg/dl, or calculated creatinine clearance ≥ 60 ml/min.  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 22 10. Bilirubin ≤ upper limit normal [ULN], alanine aminotransferase [ALT] ≤ 1.[ADDRESS_1136221] and/or 
aspartate aminotransferase [AST] ≤ 1.[ADDRESS_1136222], alkaline phosphatase ≤ 2.[ADDRESS_1136223].  
11. Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.[ADDRESS_1136224].  
12. Activated partial thromboplastin (aPTT) time ≤ 1.[ADDRESS_1136225] a negative urine or serum pregnancy at screening (pregnancy test 
is not required for patients with bilateral oophorectomy and/or hysterectomy or for those 
patients who are > 1 year  postmenopausal). 
14. All patients of reproductive potential must agree to use a medically acceptable form of contraception (e.g., hormonal birth control, double-barrier method) or abstinence.  
3.[ADDRESS_1136226] injection of Ad/PNP.  
5. Received radiation treatment < [ADDRESS_1136227] injection of Ad/ PNP and  does not have 
any RECIST 1.1 evaluable lesions that are outside the radiation field. (If  the patient has 
RECIST 1.1 evaluable lesions outside the radiation field then they can be included.) 
6. Received chemotherapy (systemic anticancer treatment) < [ADDRESS_1136228] injection of Ad/PNP and have not recovered from all the related side effects. (If the patient has recovered from all related side effects or has reached a new baseline, then they may begin  receiving 
treatment  at sooner  than 4 weeks ). 
7. Have significant baseline neuropathy (> G rade 2 based on Common Terminology Criteria for 
Adverse Events [ CTCAE ] v5.0) 
8. Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease, active infection) 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 23 9. Had within 6 months prior to enrollment: m yocardial infarction ( MI), cerebral vascular 
accident (CVA ), uncontrolled c ongestive heart failure ( CHF ), significant liver disease, 
unstable angina. 
10. Fever (temperature > 38.1oC orally).  
11. Receiving chronic systemic corticosteroids (> 3 weeks) or any chronic immunosuppressive 
medications within [ADDRESS_1136229] injection of Ad/PNP. Subjects receiving short courses of corticosteroids are considered eligible for the study. 
12. Receiving anticoagulants other than those to maintain patency of venous lines.  
13. Women who are pregnant or breast feeding. 
14. History of human immunodeficiency virus ( HIV) infection. No requirement for testing.  
3.[ADDRESS_1136230] ( IRB) approved informed consent prior to participation in any study 
specific procedure. The participant must receive a copy of the signed and dated consent document. 
The original signed copy  or certified copy of the consent document must be retained  in the medical  
record  and research file. This signed consent form present in the medical record shall be considered 
documentation that the GCP informed consent process has been completed.  
3.[ADDRESS_1136231]  Withdrawal 
While subjects are encouraged to complete all study evaluations, they may withdraw from the 
study at any time and for any reason. Subjects receiving chemotherapy (other than F -araAMP) or 
radiation therapy will be removed from the study. Participation is voluntary, and declining to 
participate  will involve no penalty,  or loss of benefits to which  the participant is otherwise entitled. 
The subject will be encouraged to maintain contact [CONTACT_819972]. Individuals who withdraw early from treatment will 
be asked to complete Day 56 (of the last treatment cycle) study visit evaluations. 
Subjects who withdraw or complete the study are not eligible to re-enter or be treated in the study 
again. Subjects who drop out following administration of study agent will not be replaced. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136232] initials,  and 
reason(s) for screen failure. No data other than reason for screen failure and basic screening data 
will be collected  on Screen  Failures.  Participants  who fail screening  will not be followed for safety 
or activity of study drug, and no other study procedures will be performed. Screen failures will  be 
replaced.  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 25 4. TREATMENT PLAN 
4.1 Dose and Dose Rationale 
The dose selected for evaluation with repeat administration has been chosen based upon tumor 
response and safety of the vector (Ad/PNP) and prodrug (F -araAMP) seen with single 
administration of this dose level in the completed Phase [ADDRESS_1136233] will 
receive a total dose of 6 x 1011 VP Ad/PNP followed by a total dose of 75 mg/m2 F-araAMP.  
4.2 Administration of Ad/PNP -F-araAMP per Cycle 
With  each cycle,  subjects will receive 3 intratumoral administrations  of 2.0 X 1011 VP Ad/PNP over 
2 days followed by 3 daily infusions of 25 mg/m2 F-araAMP in the outpatient clinic or in -hospi[INVESTIGATOR_819951]. The physician or a designee trained to do the injections by [CONTACT_1268] ( PI) will administer intratumoral Ad/PNP during each cycle. The outpatient 
unit is staffed with medical personnel to treat emergency and non- emergency medical  events.  
Ad/PNP will be given via direct intratumoral injection three times over 2 days. If needed, the 
investigator may utilize  radiologic guidance (e.g., ultrasound) to assist  in the injection  of Ad/PNP. 
Two intratumoral  administrations will be given on Day [ADDRESS_1136234] 
intratumoral administration will be given on the morning of Day 2. 
Vials of Ad/PNP will be thawed and prepared for injection by [CONTACT_819973]. In the Phase  1 study, Ad/PNP 
was administered intratumorally  in a 0.5 ml volume (~2 x 10
11 VP/ml or ~2 x 1012 VP/ml); both 
dose levels showed activity and were well  tolerated. In the Phase 1/2 study, 2 x 1011 VP will be 
administered in volumes up to 5 ml (4 x 1010 VP/ml) so that vector can be dispersed more 
effectively throughout needle- assessable tumor tissue.  
The volume of vector injected  into each tumor will be according to tumor volume. All measurable 
tumors that are accessible  for intratumoral injection  will be identified  and treated  for each enrolled 
subject  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 26 Subjects  will receive a total of 2 x 1011 VP Ad/PNP  per injection  (3 injections  per cycle)  distributed 
across  the injected  tumors and volume of vector  will vary dependent upon estimated  tumor volume 
using the tumor’s two dimensions measured by [CONTACT_819974] - 
Injection of Investigational Product into the Tumors of Human Subjects. For example, for a subject 
with 3 tumors of 1.5 ml, 3 ml, and 5 ml size each, 2 x1011 VP Ad/PNP will be suspended in 3.5 mL 
and tumors injected with 0.5 mL, 1.0 mL, and 2.0 mL, respectively. If the  tumor mass  is very large 
or the total volume for all discreet  tumors exceeds  16 ml, a portion of the tumor mass or certain 
discrete tumors will be selected by [CONTACT_819975] 5  ml of Ad/PNP. The same 
tumors will be injected with each administration of 5 ml Ad/PNP.  
Lesion Volume  Injection Volume  
> 16 ml  5.0 mL  
12 ml to 16 ml  4.0 mL  
8 ml to 12 ml  3.0 mL  
4 ml to 8 ml  2.0 mL  
2 ml to 4 ml  1.0 mL  
Less than 2 ml  0.5 ml  
 
 
Using aseptic technique, the Ad/PNP solution will be injected percutaneously with injection at 
multiple sites within the tumor to achieve thorough infiltration. A subcutaneous injection of local 
anesthetic may be used, if desired.  
Approximately [ADDRESS_1136235] administration of Ad/PNP into the tumor 
(Day  3), subjects will receive 25 mg/m2 F-araAMP daily for 3 days. F -araAMP will be prepared 
and administered intravenously over approximately 30 minutes per the package insert. Subjects 
who do not receive all three administrations  of Ad/PNP  will not receive F- araAMP;  all subjects  
will be assessed for safety at the scheduled study visits . Subjects who do not receive all three full 
doses of Ad/PNP may be eligible to receive subsequent doses of F -araAMP at the discretion of the 
investigator. 
In this study, each 5-day course of treatment  will commence every  28 days +/- 3 days and subjects 
will receive up to 5 cycles of Ad/PNP -F-araAMP. The 28- day interval complies with the 
recommended dosing schedule between courses of F -araAMP used to treat hematological 
malignancies. Treatment will be discontinued prior to 5 cycles in the event of injected tumor 
progression (and/or the i nvestigator determines the patient may no longer stand to benefit from further 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 27 treatment) or if there  is no tumor present  for injection.  In the event  that treatment is discontinued, the 
subject should complete the Day [ADDRESS_1136236] treatment cycle. 
Subjects will be monitored for clinical safety events and changes in laboratory parameters 
throughout the study period. Subjects who experience a CR before the next cycle will not receive treatment  but will continue to be followed during the study period. Subjects  whose tumors achieve 
a CR but then recur during the study period may resume treatment with Ad/PNP-F- araAMP up  to 
the maximum allowed 5 total cycles.  
No formal follow -up visits are planned following the end of the study period (Day [ADDRESS_1136237] 
treatment cycle). However, the Investigational New Drug ( IND) Sponsor may request follow -up 
information from the i nvestigator on tumor status in subjects who have stable disease (SD), PR, or 
CR at completion of their study participation. 
4.3 Dose  Modification 
Based  on monitoring of efficacy  signal from  subjects  completing  treatment,  if no anti-tumor activity 
and no DLTs  are observed, GeoVax  may increase the dose of vector  administered  5-fold from to  
2 x 10
11 VP/dose to 1 x 1012 VP/dose, which was the high dose of vector used in the P hase [ADDRESS_1136238] possibly related to Ad/PNP -F-araAMP and occurring up to 28 days after initiation 
of dosing on Cycle 1 Day 0. Formal approval from the Food and Drug Administration ( FDA ), IRB, 
and other regulatory offices as needed will be obtained prior to initiating an increase of vector 
dose. No serious toxicities were detected with this dose of vector (1 x 1012 VP/dose) in the earlier 
Phase 1 trial.  
The total dose of F -araAMP per cycle is lower than that recommended to treat patients with 
hematological malignancies. Subjects who experience greater than G rade 2 neurotoxicity should 
be discontinued from treatment and followed for safety. The i nvestigator may decrease the dose 
of F-araAMP to 15 mg/m2 or delay administration based on evidence of high grade (CTCAE v 5.0 
Grade 3 or higher) hematologic or nonhematologic toxicity not recovered to baseline by [CONTACT_4475] 1 of 
each subsequent cycle, with the exception of  isolated lymphopenia, which will not require a dose 
reduction. Subjects  who require  further reduction in F-araAMP  in the judgment of the investigator, 
based upon recurrent high grade  AEs not resolved by [CONTACT_4475] 1 of the subsequent cycle should be 
discontinued from treatment and followed for safety. Growth factor support is not to be used 
prophylactically in this study. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136239] been  reported  in clinical  studies evaluating  other non- replicating 
adenoviral vectors  injected  intratumorally.  The Phase 1 study evaluated  two dose levels  of Ad/PNP 
(1011 VP/dose in Cohorts 1- 3 and approximately 1012 VP/dose in Cohort 4) and 3 dose levels of 
F-araAMP (5, 15, and 25 mg/m2 in Cohorts 1, 2, and 3, respectively and 25 mg/m2 in Cohort 4). 
Among the [ADDRESS_1136240] frequently reported TEAEs were injection site pain 
(11 subjects, 91.7%) and fatigue (8 subjects, 66.7%). Injection site pain was reported in all but 
[ADDRESS_1136241] receiving 1011 VP/dose + 15 mg/m2 F-araAMP. The event was assessed as treatment - 
related in 10 subjects (83.3%); most reports were Grade 1 or 2 in severity. All Grade ≥[ADDRESS_1136242] receiving 1012 VP/dose experienced  severe 
(Grade 3) injection site pain on Day 1 that was assessed as definitely related to Ad/PNP  injec tion. 
The subject went on to complete the study receiving lidocaine injection prior to injection of 
Ad/PNP. Other injection site reactions included injection site discharge (4 subjects receiving either 
1011 or 1012 VP/dose, 33.3%); injection site erythema, hemorrhage, and pruritus (2 subjects each 
receiving 1011 VP/dose, 16.7%), and injection site paresthesia ([ADDRESS_1136243] receiving 1012 VP/dose, 
8.3%). All of these events were reported in only [ADDRESS_1136244] within a cohort and all were assessed as 
Grade 1 or 2 in severity; most were reported as treatment -related.  
F-araAMP is a purine analog used to treat patients with chronic lymphocytic leukemia ( CLL) . 
Besides being an anti -tumor agent against  lymphoid malignancies,  F-araAMP  has 
immunosuppressant activity  and is incorporated in preparatory regimens for allogeneic bone 
marrow  transplantation. 
When administered in cycles of the standard 25 mg/m2 five-day course, F -araAMP  induces 
myelosuppression (neutropenia, thrombocytopenia and anemia). Other commonly reported AEs 
include fever and chills, infection (including opportunistic infections), nausea and vomiting, malaise, fatigue, anorexia, and weakness. Life -threatening autoimmune hemolytic anemia has 
been reported in patients receiving F -araAMP. Objective weakness, agitation, confusion, visual 
disturbances, and coma have occurred in CLL patients treated with F -araAMP at the recommended 
dose. A high incidence of opportunistic infections, including Pneumocystis jirovecii  pneumonia 
has been seen in CLL patients, especially those with a substantial history of steroid or alkylator use. Reactivations of latent viral infections such as VZV (herpes zoster), Epstein- Barr virus and 
JC virus (progressive multifocal leukoencephalopathy) have been  reported in patients treated with 
F-araAMP. Additional information concerning drug related effects reported with F -araAMP  are 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 29 described more fully in the package insert. It is unknown at this  point whether any of these 
toxicities will be more or less pronounced when F -araAMP is given in conjunction with the 
Ad/PNP with repeat  administration.  
The toxicity attributable to intratumorally generated F -Ade with repeat injection is unknown. 
Based on results from a nonclinical study, systemic exposure to levels of F -Ade higher than 
expected in this study may cause myelosuppression and/or elevation in liver enzymes. Review  of 
the safety and laboratory data from the Phase 1 clinical study showed that 2 of the 12 subjects 
experienced  Grade ≥ 3 lymphopenia (neither  were assessed  as definitely  related  to study treatment) 
and no subject  had elevation  in liver enzymes.  One of the two subjects  with Grade ≥ 3 lymphopenia 
received  5 mg/m2 F-araAMP  and the other received  25 mg/m2 F-araAMP  daily  for [ADDRESS_1136245] developed a bacteremia related to a central intravenous line and another had a chronic wound over the tumor being injected. There were no reports of opportunistic infections. 
4.4.1 Infection  Prophylaxis 
Although the dose regimen of F -araAMP is shorter than that used to treat hematological 
malignancy, there remains a potential risk for Pneumocystis jiroveci  (PJP) infection with repeat 
cycles. Consequently, all subjects will receive prophylaxis antibiotic treatment, e.g., one double - 
strength trimethoprim (TMP)/sulfamethoxazole (SMX) (i.e., 160 TMP/800 SMX) three times a 
week. Prophylaxis will start prior to Day [ADDRESS_1136246] infusion of F -araAMP. Alternativ e acceptable prophylactic treatment may be used and  
should be recorded. 
Additional prophylactic antibiotic therapy may be initiated in subjects with clinically relevant 
reduction in white blood cell counts per the investigator’s assessment. 
4.5 Stoppi[INVESTIGATOR_819952]: 
• Death attributed to study drug; 
• Serious systemic anaphylactic tumor injection  reaction; 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 30 • Serious rare reactions to F -araAMP, such as blindness or coma.  
The FDA, Office of Biotechnology Activities/National Institutes of  Health (OBA/NIH) , IRB and 
SMC will be notified immediately if one of these AEs occurs and a comprehensive review of the 
safety data will be conducted prior to resumption of dosing. In addition, findings from the review 
will be relayed to and discussed between the SMC and Sponsor (GeoVax) . Should the SMC and 
GeoVax  agree to stop the study, GeoVax  will inform all investigational sites and the appropriate 
regulatory bodies of the decision to st op the study at all sites . 
4.6 Drug  Accountability  
The investigator will be responsible for dispensing and accounting of Ad/PNP provided by [CONTACT_457410]. The investigator will also be responsible for documentation of lot numbers, dose 
and administration  of Ad/PNP -F-araAMP  given during the study. Under no circumstances  will the 
investigator supply vector  to other investigators, allow  vector  to be used other  than directed  by [CONTACT_47375], or destroy or dispose of vector in any other manner without prior authorization from the 
IND Sponsor. 
Any residual vector must be returned to the investigational pharmacy for disposition. The site’s Investigational Pharmacy  will dispose of all unopened or partially  used vials  of Ad/PNP  at the end 
of the study. Please see the Pharmacy Manual for full and current details.  
4.7 Concomitant Medications  
All medications taken at the time of study entry will be recorded. Any changes in concomitant medication, including additions, discontinuations, and dose changes, occurring during study participation will be recorded.  
The following concomitant treatments are permitted during the  study: 
• All supportive measures (including antiemetics, red blood cell  transfusions, antibiotics) 
consistent with optimal patient care will be given throughout the study and should be 
documented in the case report form (CRF).  
• Colony- stimulating factors and erythropoietin may be used during the study if  clinically 
indicated according to the American Society Clinical Oncology guidelines. However, 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 31 neither granulocyte colony- stimulating factor ( G-CSF) nor granulocyte- macrophage 
colony- stimulating factor  (GM-CSF) will be used prophylactically in this study. 
The following concomitant treatments are not permitted during the study: 
• Allopurinol 
• No systemic anticancer agent other than the study drug 
• Palliative radiation therapy (if a subject has need for palliative radiation, they will be 
removed from the study) 
• Subjects that develop symptomatic pleural effusion/pericardial effusion will be taken off 
study, and treated with standard therapi[INVESTIGATOR_014]  
• No other investigational therapi[INVESTIGATOR_819953].  
4.8 Criteria for Removal from  Study  
Treatment will be stopped and patients will be removed from study due to unacceptable AEs , 
withdrawal of consent, or non- compliance.  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 32 5. INVESTIGATIONAL AGENT/DEVICE/PROCEDURE  INFORMATION 
5.1 Description of Study Drug  
Study drug for administration to the subjects consists of the vector Ad/PNP for intratumoral 
administration and F-araAMP for intravenous administration. 
F-araAMP (fludarabine phosphate) is licensed as a treatment for hematological malignancies but 
lacks efficacy to treat solid tumors. In the nonclinical studies, administration of the Ad/PNP vector 
intratumorally alone had little or minimal activity on tumo r size. F -araAMP  is being administered 
as a prodrug where subsequent generation of F -Ade within tumor cells transfected with the vector 
is expected to have local anti -tumor effect on the solid tumor. Commercial  F-araAMP  (fludarabine  
phosphate) available from  the site’s  formulary  will be used in this study. 
The vector,  Ad/PNP,  is manufactured  by [CONTACT_819976] -Aldrich, 
SAFC Pharma (Carlsbad,  CA). 
Ad/PNP will be supplied as a liquid formulation in vials containing 2 x 1011 VP/100 µl  in 20 mM 
Tris (pH 8.0), 25 mM NaCl, 2.5% Glycerol and should be stored at less than -60o C. Dilutions of 
the vector in sterile normal saline USP will be made immediately prior to use. Following  dilution, 
the investigational pharmacy will send the vector to the clinic on ice for administration. Vector should be administered  as soon as possible after dilution and must be used within  6 hours of thaw. 
The vector  will be admin istered  percutaneously via injection  into the tumor mass.  A subcutaneous 
injection of local anesthetic may be used, if desired. 
5.2 Availability  
Ad/PNP for this project will be furnished by [CONTACT_819977] , Inc. ( Smyrna, GA). Commercially sourced 
F-araAMP will be used for this study.   
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 33 5.3 Agent  Ordering  
Orders for Ad/PNP will be placed with GeoVax  by [CONTACT_819978].  Ad/PNP will be transported on dry ice by 
[CONTACT_819979]’s investigational pharmacy. 
5.4 Agent  Accountability  
Each  investigator will be responsible for dispensing and accounting of Ad/PNP provided by [CONTACT_457410]. The investigator will also be responsible for documentation of lot numbers, dose 
and administration of Ad/PNP -F-araAMP given during the study. Under no c ircumstances will the  
investigator supply vector  to other investigators, allow  vector  to be used other than directed  by [CONTACT_819980], or destroy or dispose of vector  in any other manner  without prior authorization from the 
IND Sponsor. 
Any residual vector must be returned to the investigational pharmacy for disposition. The site’s Investigational Pharmacy  will dispose of all unopened or partially  used vials  of Ad/PNP  at the end 
of the study. Please see the Pharmacy Manual for full and current details.  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 34 6. DOSE  MODIFICATIONS  
See S ection  4.3 for dose modifications of Ad/PNP and F- araAMP.  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 35 7. ADVERSE EVENTS AND REPORTING PROCEDURES  
7.1 Adverse Event  
An adverse event (AE) is any unfavorable and unintended diagnosis, symptom, sign (including an 
abnormal laboratory finding), syndrome or disease which either occurs during the study, having 
been  absent  at baseline,  or, if present  at baseline,  appears  to worsen.  For this study, only abnormal 
laboratory findings with clinical significance as determined by [CONTACT_978]  [INVESTIGATOR_508339] . 
A TEAE is defined as an AE  with onset occurring at any time point after the first intratumoral 
administration of Ad/PNP. A TEAE also may be a continuing AE  reported prior to the date of the 
first dose of study drug, which worsens in severity after the first administration of Ad/PNP. 
Disease progression is not an AE (non-serious or serious),  although signs and symptoms thereof 
may be reportable as AEs . 
7.2 Serious Adverse Event  
A SAE  (experience) is defined (21CFR312.32) as any adverse experience that suggests a 
significant hazard, contraindication, side effect, or untoward medical occurrence that: 
• Results in  death,  
• Is life-threatening (Note: the term “life -threatening” refers to an event in which the subject 
was at risk of death at the time of the event rather than to an event which hypothetically 
might have caused death if it were more severe.),  
• Requires (or prolongs) hospi[INVESTIGATOR_059],  
• Causes persistent or significant disability/incapacity,  
• Results in congenital anomalies or birth defects, or 
• Important Medical Event Requiring Medical or Surgical Intervention to Prevent Serious 
Outcome. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations,  such as important medical  events  that may not be immediately  life- 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136247] be followed until conclusion of the pregnancy (delivery  
or termination).  Administration  of study drug will be discontinued in a subject who becomes 
pregnant. The subject will be asked to complete safety evaluations through Study Day [ADDRESS_1136248]’s  last cycle (no follow -up imaging  studies for the purposes of this study will be obtained). 
If a male subject reports a pregnancy of his spouse or significant other within Day [ADDRESS_1136249] be done via e -mail 
to GeoVax_PV@cato -sms.com . 
7.[ADDRESS_1136250] estimate of the i nvestigator at  the time of the 
reporting of the causal relationship between the study drug and an AE . 
The following study drug relationships will be used for this clinical study: 
Unrelated : There is no temporal relationship between the event and the administration of the study 
drug, and/or the event is clearly due to the subject’s medical condition, other therapi[INVESTIGATOR_014], or accident. 
Possibly Related : There is some temporal relationship between the event and the administration 
of the study drug and the event is unlikely to be explained by [CONTACT_2299]’s medical condition 
or other therapi[INVESTIGATOR_014]. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 37 Probably Related : The temporal relationship between the event and the administration of the 
study drug is compelling, and the participant’s medical condition or other  therapi[INVESTIGATOR_819954].  
Definitely Related : The temporal relationship between the event and the administration of the 
study drug is compelling, the participant’s medical condition or other therapi[INVESTIGATOR_819955] a known or suspected response pattern to the medication. 
The categories of Definitely, Probably, and Possibly are considered study drug related. 7.4 Severity of the Adverse Event  
Adverse events will be graded per  National Cancer Institute  (NCI) C TCAE  v5) 
(http://evs.nci.nih.gov/ftp1/CTCAE/about.html ). 
• Mild (Grade  1) 
• Moderate (Grade 2) 
• Severe (Grade 3) 
• Life –Threatening (Grade 4)  
• Fatal (Grade 5)  
7.[ADDRESS_1136251] all observed AEs  in the CRF. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136252]  and/or in response to an open  question from 
study personnel or revealed by [CONTACT_4171], physical examination, or other diagnostic procedures 
are to be recorded in the study specific worksheets. Any clinically relevant deterioration in 
laboratory assessments or other clinical findings, as assessed by [CONTACT_941] i nvestigator, is considered an 
adverse event and must be recorded on the appropriate pages of the CRF. Whenever possible, 
symptoms should be grouped as single syndrome or diagnosis. The i nvestigator should specify the  
date of onset, maximal intensity,  corrective therapy given, outcome, and his/her assessment  of 
causality (i.e., whether the adverse event was related to the study drug) (Section 7.3). 
From signing of informed consent through initiation of study treatment, only SAEs  considered 
related to study procedure(s) should be recorded. After initiation of study treatment  (Day  1) through 
Day [ADDRESS_1136253]’s  last treatment  cycle,  all adverse events  regardless of seriousness or 
relationship to study drug should be recorded. 
Serious adverse events considered related to prophylactic antibiotic treatment (and not suspected 
to be related to study treatment) are expected AEs . They should be collected but are not subject to 
expedited reporting. 
Any AE that is not resolved by [CONTACT_819981]’s withdrawal will be followed as clinically indicated 
until its resolution, or if non-resolving, until considered stable. 
7.5.[ADDRESS_1136254] subjects prior 
to administration of study drug to report any physical changes or new symptoms that they notice 
during the course of the study. 
Non-serious AEs and SAEs  related  only to prophylactic antibiotics  will be reported annually to 
FDA and NIH Office of Science Policy via an Annual Report (by [CONTACT_819982] ) and to 
IRB via Continuing Review (by [CONTACT_819983]).  
The P I  must report all SAEs  and deaths, whether or not considered related to study treatment, 
immediately  (within 24 hours of knowledge of event) to GeoVax . 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 39 For Serious Adverse Events/Pregnancy, please send completed report form to GeoVax_PV@cato -
sms.com  or fax to 919-361- [ADDRESS_1136255] report: 
• Treatment regimen (dosing frequency, combination therapy)  
• Protocol description (and number, if assigned)  
• Description of event, severity, treatment, and outcome, if known 
• Supportive laboratory results and diagnostics 
• Investigator’s assessment of the relationship of the adverse event to each  investigational 
product and suspect medication  
The P I should report any follow-up information as it becomes available. 
Adverse events  meeting  the IRB definition  of ‘Unanticipated  Problem’ will be reported  to the IRB 
within 10 working days of investigator determination event meets reporting requirements, or 
within 5 working days for deaths or life- threatening  experiences.  
Adverse events deemed serious and related to study drug or study procedures (regardless of expectedness) will be reported to any applicable oversite board at the site  within 5 working days 
of knowledge of event. 
Adverse events deemed serious, unexpected (i.e. , not described in the protocol, Investigator’s 
Brochure or informed consent documents) and related to study drug must be reported to GeoVax  
using the SAE Report Form  within [ADDRESS_1136256]  information  listed  
above. The Sponsor is responsible for reporting any event  meeting  IND Safety Reporting criteria 
to FDA. SAEs considered related to antibiotic treatment are considered expected.  
7.5.3 Safety Monitoring Committee  
The SMC will meet and review s afety data (i.e., adverse events reporting, reactions to study drug, 
deaths, etc.)  and protocol deviations at time intervals specified in the SMC C harter  and at any other 
time when it is determined by [CONTACT_313578] C or GeoVax  that such a review is warranted. The SMC will 
be comprised of, at a minimum, a Sponsor representative, medical monitor  (SMC facilitator) , and 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136257] igative site  designees  from each participating site . Only the investigative site designees will 
be voting members of the SMC. SMC voting members will be experienced professionals in 
evaluating safety and efficacy data derived from oncology clinical trials. The medical monitor and 
Sponsor representative will be part of the SMC but will not be voting members. Observers without 
voting rights are also allowed to join the SMC meetings. All SM C recommendations will be 
documented and communicated to GeoVax  and the investigators at each study site . Following their 
review, the  SMC  will recommend whether or not dosing may continue or the need for 
modifications  to the protocol and/or safety monitoring.  
In addition, an ad hoc SMC meeting can be planned on initiative from the Medical 
Monitor/Sponsor based on the regular surveillance of the safety data and/or upon request from an 
investigator. The SMC may recommend stoppi[INVESTIGATOR_819956]/or frequency of AEs  is observed.  
8. CORRELATIVE/SPECIAL STUDIES  
Special studies to assess safety and efficacy of Ad/PNP with F -araAMP are planned and will be 
conducted by [CONTACT_819984] (with IRB approval at that institution) or outsourced to commercial organizations specializing in testing of this sort. These studies are described in Section 9.1 (Procedures Table) as well as Sections 9.2 and 9.3, and include: 1) blood 
samples  for adenovirus, 2) urine for adenovirus, 3) blood samples  for antibody against  adenovirus, 
4) F-Ade plasma level, and 5) tumor biopsy for studies of PNP activity, histochemistry, tumor 
growth fraction,  and adenoviral  distribution. Samples  will be shipped to Emory  or commercial  site 
with the same strict attention to patient confidentiality described throughout the protocol. Please 
also see Section  10. 
Methods regarding tumor biopsy and analysis, as well as serum F -A
 de to be arranged by 
[CONTACT_819985]:  
1) Measurement of E. coli PNP activity . Approximately [ADDRESS_1136258] transgene expression observed 
in our preclinical studies and will allow us to ascertain E. coli PNP activity at the beginning 
of F-araAMP treatment. Tissue samples will be immediately frozen and stored at -80°C. 
Crude extracts will be prepared and incubated with 50 mM potassium phosphate, 100 µM 
6-methylpurine-2’- deoxyriboxide (MeP -dR, a standardized E. coli PNP substrate), and 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 41 100 mM HEPES buffer (pH 7.4) at a concentration of tumor  lysate that results in a linear 
reaction over the incubation period. The formation of 6- methylpurine will be monitored using 
reverse phase high performance liquid chromatography ( HPLC ). Care will be taken to 
thoroughly homogenize samples in order to release PNP enzyme.  
2) Metabolism of F -araAMP . An important measurement to evaluate effectiveness of vector 
delivery is to quantify active metabolites in tumor tissue following F -araAMP treatment, with 
the goal to determine levels of F -Ade produced from F -araAMP by E. coli PNP. F -Ade in 
tumor tissues is activated by [CONTACT_819986] F -Ade - containing nucleotides 
(primarily F -ATP) and incorporated into RNA, which is responsible for cell killing action of 
F-Ade. For this measurement, tumor tissue will be obtained using a dermal punch from the 
tumor site one hour after the final F -araAMP treatment on Day 5. We have shown in mouse 
tumor xenografts that F -Ade metabolites are retained in tumor parenchyma for prolonged 
periods ( t½ greater than 24 hours ) and  obtaining tumor samples one hour after the final 
injection of F -araAMP should allow for  an assessment of F -Ade tumor levels attributable to 
cumulative administration of prodrug. Because cellular nucleotides rapi[INVESTIGATOR_819957], we plan to measure total F -Ade levels by [CONTACT_819987] (in the presence of immucillin, a potent E. coli PNP inhibitor) to 
degrade all F -Ade nucleotides to 2 -fluoro -adenosine (F -Ado). We will utilize an liquid 
chromatography/mass spectrometry ( LC/MS ) method to measure both F -Ade and F -Ado. 
Since tumor cells may also contain F -araA nucleotides, we will configure a parallel LC/MS 
method to measure F -araA. Please note that investigators in this project have access to LC/MS 
protocols specifically for analysis of nucleoside and related compounds, and over 20 years’ 
experience with measurements of this type.  
3) Plasma levels of F- Ade. It will be important to determine the extent to which F -Ade escapes 
into the general circulation, and we will monitor systemic release of the compound. Plasma 
samples will be obtained after F -araAMP injection on D ays 3 and 5, and analyzed for F -Ade, 
F-Ado, and F -araA using LC/MS procedures familiar to our laboratories. In our Phase 1 study, 
no F-Ade was measurable in plasma with an LC/MS assay of sufficient sensitivity to detect 
F-Ade at levels approximately [ADDRESS_1136259] -level 
(NOAEL ) in rats given the compound daily for 7 days. 
4) Tumor growth fraction and effects on the stem cell compartment, and evidence for PNP 
protein expression . Tumor punch biopsies obtained above will also be studied by 
[CONTACT_819988] (e.g., Ki67) or the tumor stem cell 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 42 compartment (e.g., SOX2, Nanog, Oct -4, CD44+/CD24+). Comparisons will be made to 
original (pretreatment) tumor sections. We will also use the biopsy samples to evaluate levels 
of PNP expression and adenoviral localization by [CONTACT_819989]. A portion of each biopsy (e.g., 10%) will be placed in RNA -later for analysis of the same antigens by [CONTACT_937]- PCR.  
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 43 9. STUDY CALENDAR  
9.1 Study Procedures  Table  
Enrolled subjects will follow the schedule of evaluations provided below. 
  Cycles 1 -5 (28 -day cycles)[ADDRESS_1136260] 
cycle  
Visit  1 2 3 4 5 6 7 8 9 
Day Screen  
-30 to 0 1 2 3 4 5 14± 2 28 ±3  56 ±[ADDRESS_1136261] injected tumor  
site(s)    X X X X X X X 
Performance Status  X X        
ECG  X        X 
CXR (If no chest CT)  X         
Chemistries2 X X8     X X X 
Hematology3 X X8     X X X 
CD4/CD8 T -cell 
subsets  X   X11     X11 
Urine analysis  X        X 
Serum pregnancy  X         
PT/aPTT  X         
CT scan/MRI4  X      X  (X) 
Physical measurement  of 
tumor size5 X X    X X X X 
Blood samples for  
Adenovirus6  X X       
Urine for adenovirus6  X X       
F-Ade plasma level     X9  X9    
Blood sample for  
antibody to adenovirus   X10      X10  
Intratumoral 
administration Ad/PNP7  X X       
PJP Prophylaxis13  X       X 
Tumor Biopsy14    X  X X   
Infusion of F -araAMP     X X X    
Adverse Events   X X X X X X X X 
Medications15 X X X X X X X X X 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 44 1. A thorough physical examination will be done at screen and second study visit; system -oriented examination 
will be conducted as needed on other visits. Weight and height should be recorded at baseline. Injected tumor 
will be examined at each visit.  
2. Chemistries include: Na+, K+, CO 2, Cl, glucose, Mg++, Ca++, blood urea nitrogen (BUN ), creatinine ( Cr), 
phosphorus, albumin, alkaline phosphatase,  ALT,  AST, total bilirubin, total protein.  
3. Hematology values include CBC with differential and platelet count.  
4. CT or MRI Imaging is to be done in all subjects at Screen and at Visit [ADDRESS_1136262], second (if PD after first 
cycle), third, and last cycle. Subjects with CR, PR, or SD in the injected tumor at Day [ADDRESS_1136263] imaging on Day  56. 
5. For injected tumors palpable on physical examination, tumor size is to be assessed by [CONTACT_819990] (ruler or calipers), if  possible.  
6. Samples will be collected prior to the first administration of Ad/PNP on Day 1 and 2 (+/-1 hour) hours after the 
third administration  on Day [ADDRESS_1136264]  cycle.    
7. Ad/PNP will be administered intratumorally three times: two administrations 3 -6 hours apart on Day 1 and 1 
administration early (morning) on Day 2. Subjects will be monitored continuously for 1 hour after each  
administration.  
8. Blood sample to be drawn and routine chemistry and hematology results reviewed by [CONTACT_819991].  
9. Draw two blood samples for F -Ade: one prior to F -araAMP infusion and one 15- [ADDRESS_1136265] administration of Ad/PNP on the first and third cycle, and Day [ADDRESS_1136266]  cycle.  
12. Evaluations on Visit 2 through 7 are to be done for each 28 -day cycle.  
13. Prophylaxis for Pneumocystis jiroveci (PJP) extends pre -dose dose on Day [ADDRESS_1136267] cycle. This  will be one double -strength  trimethoprim  (TMP)/sulfamethoxazole (SMX)  (i.e., 160 
TMP/800 SMX)  three  times a  week.  
14. Biopsy of injected tumor will be done on Days [ADDRESS_1136268] cycle. 
15. Medications will be recorded at screening and any change in medications will be recorded at study visits.  
16. Vital signs will be recorded at 30 +/- 15 min, and 60 +/ - 15 minutes following each administration 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 45 9.2 Study  Procedures  
Subjects screened and enrolled will follow schedule of evaluations provided at the beginning of 
this protocol. The following evaluations will be performed: 
9.2.1 Visit 1 (Day -30 to 0, Screening and Baseline Laboratory Values)  
The following evaluations and tests will be performed: Preliminary Screening: 
• Obtain written informed  consent 
• Medical history including current medication  
• Assessment of performance status  
• Physical  examination  
• Record vital  signs 
Complete screening if entry criteria are met on preliminary screening:  
• Electrocardiogram  (ECG) 
• Chest X -ray if no chest CT. Chest radiograph within two weeks prior to screening may be  
used 
• Blood samples for: Hematology, CD4/CD8 T- cell subsets, Chemistry,  PT/aPTT 
• Serum pregnancy test in women of childbearing potential 
• Urine  analysis  
• Assessment of tumor with CT scan or MRI  
 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 46 For injected tumors palpable on physical examination, measurement with calipers or rulers, if 
possible, with photo documentation. 
During each 28 -Day Cycle of Ad/PNP -F-araAMP:  
The following tests and evaluations scheduled on Visits 2 through 7 are to be done during each 
treatment cycle. Up to five treatment cycles are planned in the study. At each clinic visit, any 
change in concomitant medication or adverse events will be recorded.  
Note that Day 28 of a cycle is Day 1 of the next repeat cycle. Tests and evaluations to be done on 
Day 1 of each cycle (i.e., Visit 2) should be conducted prior to study drug administration unless otherwise noted. 
9.2.2 Visits 2 and 3 (Days 1 and 2 of Intratumoral Administration of Ad/PNP)  
Subjects may receive intratumoral administrations in the clinic or hospi[INVESTIGATOR_307] (in -patient) at the 
discretion of the investigator. 
The following tests and evaluations will be performed: 
• Physical exam (Day 1 only) or examination of injected tumor site(s) (Day 2 only). 
• Record vital signs. 
• Record performance status on Day 1 of cycle. 
• For injected tumors palpable on physical examination, measurement with calipers or rulers, 
if possible, with photo documentation (Day 1). 
• Obtain blood sample for hematology and chemistry prior to first administration of Ad/PNP on Day 1 of cycle. 
• Obtain blood sample for antibody to adenovirus prior to the first administration of Ad/PNP on Day [ADDRESS_1136269] cycle. 
• Obtain blood samples for measurement of adenovirus level prior to first administration of Ad/PNP on Day [ADDRESS_1136270] administration of Ad/PNP on Day [ADDRESS_1136271]  cycle.  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 47 • Obtain urine sample for testing adenovirus prior to first administration of Ad/PNP on Day 1 
and 2 (+/-1 hour)  hours after the third administration of Ad/PNP on Day [ADDRESS_1136272] cycle. 
• Give two administrations of Ad/PNP intratumorally 3 -6 hours apart on Day 1 and one 
administration early (morning) on Day 2. Following each intratumoral administration the 
subject will be observed closely for tumor injection reactions or other acute safety events. Vital signs will be recorded at 30 +/- 15 min, and 60 +/ - 15 minutes following each 
administration. Non- hospi[INVESTIGATOR_819958] 1 hour of 
observation as long as the investigator considers them clinically stabl e. 
• Initiate PJP prophylaxis (Day 1). 
• Record any AEs. 
• Record  any change in medications. 
9.2.3 Visit 4 (Day 3, First infusion of F- araAMP)  
Subjects may receive F -araAMP daily in the clinic or as in -patients at the discretion of the 
investigator. 
• Examination of injected tumor site(s) . 
• Record vital  signs. 
• Obtain blood specimen prior to infusion of F- araAMP  for: 
– CD4/CD8 T -cell counts (first cycle only) 
• Obtain tumor biopsy, first cycle only. 
• Administer F -araAMP intravenously over approximately 30 minutes. 
• Blood specimen for F -Ade plasma level prior to and [ADDRESS_1136273] cycle . 
• Record any AEs. 
• Record any change in medications. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 48 9.2.4 Visits 5 and 6 (Days 4 and 5) 
• Examination of injected tumor site(s) . 
• Record vital signs. 
• For injected tumors palpable on physical examination, measurement with calipers or rulers, 
if possible (Day 5). 
• Administer F -araAMP intravenously over approximately 30 minutes. 
• Draw blood for F -Ade plasma  level prior to and 15- [ADDRESS_1136274] cycle. 
• Obtain tumor biopsy, Day [ADDRESS_1136275] cycle only. 
• Record any AEs. 
• Record any change in medications. 
9.2.5 Visit 7 (Days 14 ± 2) 
• Record vital signs 
• Examination of injected tumor site(s)  
• For injected tumors palpable on physical examination, measurement with calipers or rulers, if possible 
• Obtain blood specimen for hematology and chemistry parameters 
• Assessment of tumor with CT scan or MRI on first, second (if PD after first cycle), third and last cycle. 
• Obtain tumor biopsy, third cycle only. 
• Record any AEs. 
• Record any change in medications. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136276] Cycle  
9.2.6 Visit 8 (Day 28 ± [ADDRESS_1136277] Cycle) 
• Examination of injected tumor site(s)  
• Record vital signs 
• Record any new or resolution of adverse events 
• Record any change in medications 
• For injected tumors palpable on physical examination, measurement with calipers or rulers, 
if possible 
• Blood specimen for: 
– Hematology 
– Chemistry  
– Antibody to adenovirus (last cycle) 
9.2.7 Visit 9 or Termination Visit (Day 56 ± [ADDRESS_1136278] Cycle) 
• Examination of injected tumor site(s)  
• Record vital signs 
• Record any new or resolution of adverse events 
• Record any change in medications 
• For injected tumors palpable on physical examination, measurement with calipers or rulers, 
if possible 
• ECG  
• Obtain blood specimen for: 
– Hematology 
– Chemistry  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 50 – CD4/CD8 T -cell counts  
• Urine analysis  
• MRI or CT scan for subjects who had CR, PR, or SD following last cycle 
9.3 Description of Evaluations 
9.3.1 Laboratory Evaluations 
Hematology values  include complete  blood count (CBC)  with differential  and platelet  count. CD4 
and CD8  T-cell subsets will be obtained at baseline  and at specified  time points following infusion 
of F- araAMP.  
Chemistry values include Na+, K+, CO 2, Cl, glucose, magnesium ( Mg++), calcium ( Ca++), blood 
urea nitrogen ( BUN), creatinine ( Cr), phosphorus, albumin, alkaline phosphatase, ALT, AST, total 
bilirubin, total protein. 
Blood samples for F -Ade plasma measurement will be drawn prior to and 15- 30 minutes after 
infusion of F-araAMP (See Study Procedures Table)  F-Ade plasma levels will be measured by  
[CONTACT_819992]. Blood and urine samples will be collected prior to the first 
administration  and [ADDRESS_1136279]  administration  of Ad/PNP  (See Study Procedures Table) 
samples  will be stored  and assayed  for adenovirus following study completion. 
Blood samples for antibody to adenovirus will also be collected prior to the first administration of Ad/PNP on the first and third cycle, and Day [ADDRESS_1136280] cycle. 
9.3.2 Physical Examination 
Vital signs include blood pressure, respi[INVESTIGATOR_1516], heart rate, and temperature. A full physical 
examination will be done at screening and at the second  study visit. At other time points in the 
study a physical that includes symptom directed examination (in addition to examination of 
tumor(s)) will be conducted as determined by [CONTACT_1003]. The subject’s height and weight will be recorded at baseline.  
Injected  tumors will be examined  at each study visit.  For injected  tumors palpable on examination, 
the tumor will be measured with ruler or calipers (if possible) and assessed for any changes as 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 51 specified in the study as shown in the Study Procedures Table . The injection site(s) will be 
examined for local reactions to the injection.  
9.3.3 Medical  History  
A complete medical history includes age, race, and/or ethnicity, past or current treatments 
including surgical, radiation treatment, and chemotherapy. Current or past illnesses, current 
medications, and use of tobacco and alcohol will be recorded at baseli ne. 
9.3.4 Tumor Response  
For this study, response will focus on the injected tumor(s) and be based on criteria according to 
those in RECIST v1.1.[6] In addition, overall tumor response will be assessed according to 
RECIST 1.1 criteria.  
The following criteria will be used to define response in injected tumor(s):  
• Complete Response (CR): Disappearance of the injected  tumor(s).  
• Partial Response (PR): At least a 30% decrease in the longest diameter (LD) of the injected tumor(s), taking as reference the smallest  LD. 
• Progression (PD): At least a 20% increase in the LD of the injected lesion(s), taking as reference the smallest LD recorded on study (this includes the baseline LD if that is  the 
smallest on study). Note: appearance of one or more new lesions will be considered 
progression in assessing overall tumor response. 
• Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient  increase 
to quality for PD taking as reference the smallest LD while on  study. 
Target tumors accessible for needle injection on physical examination will be injected. Size of the 
injected tumor masses will be measured with ruler or calipers, as possible, and it is preferable if the same practitioner measures using the same technique at each visit.  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136281] scan with the site’s available MRI 
and CT techniques. The same imaging technique will be used for all evaluations. The target lesions 
and injected tumors for intratumoral administration will be as sessed radiographically at baseline 
and within 2 weeks of Ad/PNP -F-araAMP on the first, third, and last cycle  (and during the second 
cycle for those showing P D). In subjects who have CR, PR or SD on imaging [ADDRESS_1136282]/MRI.  
9.4 Tumor Biopsies  
A sample of tumor tissue will be obtained on three occasions from one of the injected tumors: Days [ADDRESS_1136283] cycle. Biopsies will be evaluated by a number of tests intended to investigate the mechanism of tumor cell clearance including PNP expression, F-araAMP cleavage, and immunohistochemistry. 
In the event that more than one tumor was injected with Ad/PNP and the biopsied tumor has CR, 
then a tissue sample may be obtained from an alternate injected tumor.  
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 53 10. MEASUREMENTS  
10.1 Primary Outcome Measure 
Title:  
The primary  objective of the study is to evaluate the safety  of repeat  administration  of a dose level 
of Ad/PNP -F-araAMP that demonstrated anti -tumor activity in patients with advanced head and 
neck cancer in the Phase 1  study. 
Timeframe:  
Primary outcome will be evaluated on a longitudinal basis and at study completion. The study is 
expected to require 36-48 months. 
Safety Issue:  
Studies conducted here are intended to evaluate safety. 
10.2 Secondary Outcome Measure  
Title:  
The secondary objective of the study is to evaluate the anti -tumor activity of repeat administration 
of Ad/PNP -F-araAMP.  
Timeframe:  
Secondary outcome will be evaluated on a longitudinal basis and at study completion. 
Safety Issue:  
N/A, please see above  
10.3 Primary and Secondary Outcome Measures -Discussion:  
Primary Outcome Measurements for this study are directed towards safety and will be evaluated 
by: [CONTACT_115033], physical examination, vital signs, inspection of tumor site, performance status, 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136284] X -ray ( CXR) , blood chemistry, hematology, CD4/CD8 T- cell counts, urinalysis, 
PT/PTT, blood sample for adenovirus, urine for adenovirus, F -Ade plasma level, blood sample for 
antibody against adenovirus, and monitoring adverse events. Additional detail regarding these 
endpoints is furnished in Section 9.1, 9.2, and 9.3. 
Secondary Outcome Measurements are directed towards efficacy and will include: Objective 
response rate (ORR), defined as the percentage of patients with a best overall response (BOR) of 
a complete response (CR) or a partial response (PR). BOR is the best response achieved during the [ADDRESS_1136285] v.1.1. Other 
measurements will include: 
• Durable response rate defined as a BOR of CR or PR for injected tumors and overall,  as 
determined by [CONTACT_393] v. 1.[ADDRESS_1136286] 4 weeks. 
• Time to response (TTR) defined as time from first intratumoral injection to date of first 
response value of CR or PR  for injected tumors and overall,  as determined by [CONTACT_393] 
v.1.1. 
• Overall survival (OS) defined as time from first intratumoral injection to date of progression or  death for any cause, whichever occurs first. 
• Progression free survival (PFS) defined as time from first intratumoral injection to date of progression or death for any cause, whichever occurs first. 
• Duration of response (DOR) defined as time from first documentation of CR or PR for injected tumors and overall,  as determined by [CONTACT_393] v.1.[ADDRESS_1136287]. 
10.3.1 Relevant  Subset  
N/A 
10.3.2 Measurement  Definition  
Please see below . 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 55 10.3.3 Measurement  Methods  
Primary outcome measurement methods will include clinical evaluation (physical examination, 
medical history, performance status, vital signs, evaluation of tumor site for evidence of tissue  
injury) by [CONTACT_819993] (or their designees). Laboratory and additional 
parameters (EKG, CXR, blood chemistry, hematology, CD4/CD8 T- cell counts, urine analysis, 
PT/PTT, etc.) will be measured according to standard hospi[INVESTIGATOR_307]/clinic procedures, and as detailed 
in Section  [ADDRESS_1136288] of Ad/PNP -F-araAMP will be assessed. For this study, response will focus  
primarily on the injected tumor(s) as the target lesion(s). Any observed effect on non- injected 
tumors and overall tumor response will also be assessed and recorded. Efficacy response results 
for injected tumors, non- injected tumors, and overall will be re ported  separately. Although we will 
evaluate response of the total tumor burden, only the injected mass will be used to primarily define 
efficacy . Because there is a possibility of immune -mediated anti -tumor benefit, we will also 
evaluate total tumor burden.  
Response (CR, PR, SD, PD) is based on RECIST v1.1 ( ht
 tp://www.ctep.info.nih.gov v1.1). [6]  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 56 11. REGULATORY CONSIDERATIONS  
11.1 Institutional Review of Protocol 
The protocol, the proposed informed consent , and all forms of participant information related to 
the study (e.g. advertisements used to recruit participants) will be reviewed and approved by [CONTACT_5040]. Any changes made  to the protocol will  be submitted as  a modification  and will be approved 
by [CONTACT_535664].  
The investigator will ensure that all necessary approvals are obtained from the hospi[INVESTIGATOR_819959]. A copy of the original IRB approval for the protocol and the Informed Consent form must be forwarded to the Sponsor or their 
representative before subject enrollment can begin. The i nvestigator will retain copi[INVESTIGATOR_819960], and the Institution will make them available for review by [CONTACT_429]’s representative or the FDA upon request. The i nvestigator must inform the IRB of all 
protocol amendments and of serious or unexpected adverse events occurring during the study 
which are likely to affect the safety of the subjects or conduct of the study. The i nvestigator must 
transmit in writing IRB approval to the Sponsor or representative. 
The investigator or designee will notify the IRB when the study is placed on “hold”, completed, 
or closed to further subject enrollment. 
11.2 Safety Monitoring Plan  
Trial safety will be monitored and reviewed by [CONTACT_819994] . The 
Sponsor, GeoVax , will coordinate among all study sites to monitor safety (i.e., AE reporting, 
reactions to study drug, deaths, etc.) . GeoVax will be responsible for reporting these AEs , 
unanticipated problems, and other relevant data to the FDA and to all study sites.  
The SMC will regularly review AE  reporting associated with the research to ensure the protection 
of human subjects. Results of the SMC audit will be communicated to the Sponsor, GeoVax , the 
IRB, and the appropriate regulatory authorities at the time of continuing review, or in an expedited 
fashion, as needed. If the SMC and GeoVax  agree to stop the study, GeoVax  will inform the 
regulatory authorities and all the investigational sites  of the decision to stop the study.  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136289] prior to his/her  participation 
in the study a written Informed Consent signed and dated in accordance with U.S. federal 
regulations (21CFR 50 and 21CFR 312.60) and Health Insurance Portability and Accountability Act ( HIPAA ) authorization to use and disclose protected health information ( PHI). Subjects, their 
relatives, guardians or, if necessary, legal representatives must be given ample opportunity to inquire about details of the study. 
The IRB must approve the Informed  Consent. The written  Informed  Consent and HIPAA 
Authorization will be obtained  after the investigator has provided to the subjects  a full explanation, 
both verbally and in writing, of the purpose, risks and discomforts involved. The original signed 
and dated copy of the Informed Consent and HIPAA Authorization must be maintained in the institution’s records. The names of subjects enrolled during the study will be considered confidential. 
11.[ADDRESS_1136290] 
names will not be supplied in the IND Sponsor data. Study findings stored on a computer will be 
main tained in accordance with local data protection  laws.  
In compliance with regulatory guidelines regarding the monitoring of clinical studies and in fulfillment of the i nvestigator’s obligations to the IND Sponsor, it is required that data generated 
as a result  of the study be available for inspection, on request,  by [CONTACT_819995]. These will include all study- relevant documentation, including medical 
histories to verify eligibility, laboratory test results to verify transcription accuracy, treatment and 
diagnostic reports, admission/discharge summaries for hospi[INVESTIGATOR_819961], and autopsy reports (if available) for deaths occurring during or in temporal 
proximity to the study. 
As part of the required content of the informed consent, participants must be informed that their 
records will be reviewed by [CONTACT_244418], IND Sponsor, and regulatory agencies. Should 
access to medical record require a separate waiver or authorizat ion, it is the investigator’s 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136291] License Application is approved for the drug for the indication 
for which it is being investigated; or, if no application or license is to be filed or, if the application 
or license is not approved for such indication, until two (2) years after the investigation is 
discontinued (21CFR 312.62). 
The investigator should ensure that the following records are maintained: 
• Signed informed consent documents for all subjects 
• Patient identification code list and enrollment log 
• Record of all communications between the investigator and the IRB 
• Record of all communication between the investigator, monitoring team, and the Sponsor 
• List of subinvestigators and other appropriately qualified persons to whom the investigator 
has delegated significant study- related duties, together with their roles in  the study and their  
signatures 
• Copi[INVESTIGATOR_772476]  
• Pharmacy files containing copi[INVESTIGATOR_819962], instructions for completion of these records, and the Investigator’s Brochure 
• All other source documents (subject medical records, laboratory records, etc.) 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 59 • Investigator files containing copi[INVESTIGATOR_819963] 
(executed form FDA 1572, signed Investigator’s Agreement, Curricula Vitae for the investigator, copy of the IRB approval of the protocol and Informed Consent  forms). Note: 
Scanned documents are acceptable as source materials.  
11.7 Protocol Approval and Amendments  
Before the start of the study, the i nvestigator will submit the clinical study protocol, informed 
consent document, and any other appropriate documents to the IRB with a cover letter listing the 
documents submitted, the dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. The IND Sponsor will submit the protocol and 
appropriate documents to the FDA and OBA/NIH in accordance with legal requirements. 
The investigator will notify the IRB of all protocol amendments and administrative changes, in 
accordance with the site’s requirements. The Sponsor or designee will notify the FDA and 
OBA/NIH of all protocol amendments and administrative changes in accordance with legal requirements. Amendments must be evaluated to determine whether the informed consent 
document should be revised. 
The investigator must keep  a record  of all communication  with the IRB and, if applicable,  between 
the coordinating investigator [INVESTIGATOR_72616]. This also applies to any communication between the 
investigator (or coordinating investigator, if applicable) and the IND Sponsor or its designee.  
11.[ADDRESS_1136292] be closed at the site upon completion. Furthermore, the IND Sponsor or the investigator has the right to close a study site at any time. As far as possible, premature closure 
should occur after mutual consultation. The IRB should be notified when the study is completed or terminated. The IND Sponsor will notify FDA and OBA/NIH when the study is completed or terminated including the reason for premature termination.  
At the end of the study, all study drug must be returned, disposed of, or retained  as directed  by [CONTACT_429]. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 60 11.9 Study Monitoring and Auditing  
The Sponsor/Contract Research Organization (CRO) will monitor study conduct in accordance 
with industry standards, best practice , and all applicable regulations and may summarize various 
aspects of the study for SMC review. 
11.[ADDRESS_1136293] and compi[INVESTIGATOR_819964] (s) 
using the electronic  data capture platform. All protocol -required information collected during the 
study must be entered by [CONTACT_941] i nvestigator, or designated representative, in the CRF . Paper charts 
in the form of printouts of the electronic  medical  record  will be kept at the investigational site for 
each subject  enrolled  and stored in a locked  office with limited  access  for only research  staff.  Details  
of CRF  completion and correction will be explained to the i nvestigator. If the investigator 
authorizes other persons  to make  entries  in the CRF , the names,  positions, signatures, and initials  
of these persons must be supplied to the Sponsor. 
The investigator or designated representative should complete the CRF  pages as soon as possible 
after information is collected, preferably on the same day that a study subject is seen for an 
examination, treatment, or any other study procedure. 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 61 12. STATISTICAL  CONSIDERATIONS  
12.1 Sample  Size 
This study is an open -label , multisite , Phase 1/2 study evaluating the safety of repeat 
administration of a single dose level Ad/PNP -F-araAMP in subjects with head and neck cancer 
and who have failed or exhausted all standard or approved therapi[INVESTIGATOR_014]. No formal sample size 
estimation will be cond ucted. Approximately [ADDRESS_1136294] 10 subjects evaluable for efficacy; this number of subjects is sufficient to assess 
preliminary safety and activity to guide design of subsequent clinical studies. This study is to be 
conducted at Stanford University, Emory University, and Thomas Jefferson University.  
A total of 10 to 20 subjects in the safety population provides sufficient precision to rule out a treatment -related SAE  rate of 38.5% or more  using a  one- sided 80% upper confidence limit  as per 
the following table: 
Safety Population N  N of Events  Observed Proportion  of 
Events  One-sided 80% Upper 
Confidence Limit  
10 2 0.2000 0.[ZIP_CODE]  
11 2 0.1818  0.[ZIP_CODE]  
12 2 0.1667  0.[ZIP_CODE]  
13 3 0.2308  0.[ZIP_CODE]  
14 3 0.2143  0.[ZIP_CODE]  
15 3 0.2000  0.[ZIP_CODE]  
16 4 0.2500  0.[ZIP_CODE]  
17 4 0.2353  0.[ZIP_CODE]  
18 4 0.2222  0.[ZIP_CODE]  
19 5 0.2632  0.[ZIP_CODE]  
20 5 0.2500  0.[ZIP_CODE]  
 
 
With 10 subjects evaluable for efficacy, there is 8 3% power to reject a null hypothesis ORR of 
10% or less when the alternative hypothesis ORR  is at least 40% using a one -sided exact binomial 
test with a target alpha level of 10% (actual alpha is 7%). The null hypothesis is rejected if 3 or 
more responses are observed (i.e., observed ORR  is at least 30%) and is considered sufficient 
evidence of efficacy to warrant further study of the treatment.  
An alternative hypothesis ORR of at least 40% in this study with f ive cycles of therapy is 
considered reasonable based on the published phase I results , where 66.7% of subjects in the higher 
dosing cohorts achieved a BOR of CR or PR with a single cycle of treatment.  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 62 12.2 Assessment of Safety  Measures  
The primary endpoint of the study is safety which will be assessed on clinical examination and 
measurement of laboratory parameters.  
All subjects who receive a dose of Ad/PNP -F-araAMP will be included in the safety analysis 
population. Each subject will be followed for safety for ~ 60 days following their final study dose. 
All safety assessments including adverse events, clinical laboratory evaluations, and vital signs 
will be summarized with descriptive statistics, where appropriate, and listed in the data listings using Medical Dictionary for Regulatory Activities ( MedDRA ) terms. We consider the repeat 
administration of Ad/PNP -F-araAMP  safe if the one -sided 80% upper confidence limit of the 
percentage of subjects in the safety population experience treatment -related Serious Adverse 
Events as defined in S ection  7.2. For example,  if 2 of 10 subjects  experience a treatment related 
SAE , then the one -sided 80% upper confidence limit is 38.1%  and the repeat administration of 
Ad/PNP -F-araAMP is considered safe. 
12.3 Adverse Events  
All AEs will be coded  by [CONTACT_2942]  (SOC) and preferred  term using MedDRA  v25.0. 
Summary tables for treatment emergent adverse events will include number of occurrences of events by [CONTACT_2946] , and numbers and percentages of subjects experiencing adverse events  by [CONTACT_819996].  If a subject  has more  than one AE which  codes to  the same preferred  term,  the 
subject  will be counted only once for that preferred  term.  Similarly, if a subject has more than one 
AE within a n SOC  category, the subject will be counted only once in that SOC  category. Summary 
tables to be generated  include: summary of AEs, relationship of AEs to study drug, severity of 
AEs, AEs leading to study drug discontinuation and serious AEs. Data listings will be provided for AEs, AEs leading to study drug discontinuation, and serious AEs.  
12.4 Clinical Laboratory Results  
Results of laboratory tests from hematology and chemistry evaluations that are outside of the 
reference range will be flagged and displayed in the summary tables. Descriptive statistics (e.g., 
number of subjects, mean, standard deviation, minimum, maximum, median and interquartile)  for 
hematology and serum chemistry measurements will be calculated for each time point. The  same 
descriptive statistics will be generated for these changes from baseline for each measurement. A 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136295] measurable value prior to dosing on Day  1. All clinical  laboratory data will be 
provided in the data listing.  
12.5 Vital Signs and Physical Examination 
Descriptive statistics (e.g., number of subjects, mean standard deviation, minimum, maximum, 
and median) of vital sign measurements for systolic and diastolic blood pressure, heart rate, 
respi[INVESTIGATOR_697], and body temperature will be calculated for each measurement. Baseline is defined as the last measurable value prior to dosing on Day 1. All vital signs will be provided in the data listing.   Physical examination of individual subjects will be presented in the data listings. No 
summary tables will be provided. 
12.6 Assessment of Efficacy  Measures  
Response (CR, PR, SD, PD) is based on the Response Evaluation Criteria in Solid Tumors 
(RECIST http://www.ctep.info.nih.gov v1.1) [6] and defined in Sections 9.3.4 and  10. 
Efficacy assessments include:  
• ORR  is defined as the percentage of patients with a BOR of CR or PR.  BOR is the best 
response achieved during the [ADDRESS_1136296] v.1.1.  
• Durable response rate is defined as a BOR of CR or PR as per Section 9.3.[ADDRESS_1136297] 4 weeks. 
• TTR  is defined as time from first intratumoral injection to date of first response value of 
CR or PR for injected tumors as per Section 9.3.[ADDRESS_1136298] 
v.1.1. 
• OS is defined as time from first intratumoral injection to date of progression or death  for 
any cause, whichever occurs first. 
• PFS is defined as time from first intratumoral injection to date of progression or death for 
any cause, whichever occurs first. 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 64 • DOR  is defined as time from first documentation of CR or PR for injected tumors as per 
Section 9.3.[ADDRESS_1136299]. 
Efficacy will be assessed in the population of subjects who receive three intratumoral 
administrations of Ad/PNP and any infusion of F- araAMP.  
Descriptive statistics (number and percentage of subjects) will be used to summarize BOR, ORR, 
and durable response rate. 95% Clopper -Pearson confidence intervals will also be provided. OS, 
PFS, DOR, and TTR will be analyzed based on Kaplan- Meier methods; Kaplan -Meier curves will 
be plotted over time. The number and percentage of subjects identified to have had an event and 
those who were censored will be displayed. The median time to event and its corresponding 95% 
CI will also be produced. A listing of re sponse for subjects will be provided. 
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 65 13. REFERENCES  
1. Machiels JPH, et al., Rationale and design of LUX- Head & Neck 1: A randomised, Phase III 
trial of afatinib  versus methotrexate in patients with recurrent and/or metastatic head and neck 
squamous cell carcinoma who progressed after platinum -based therapy. BMC Cancer 2014. 
14:473. 
2. Fury MG and Pfister DG. Current recommendations for systemic therapy of  recurrent and/or 
metastatic head and neck squamous cell cancer. JNCCN, 2011. 9: 681-690. 
3. Vermorken JB, et al ., Platinum -based chemotherapy plus cetuximab in head and neck cancer. 
N Engl J Med, 2008. 359:1116-27. 
4. Peron J, et al., An effective and well -tolerated strategy in recurrent and/or metastatic  head and 
neck cancer is successive lines of active chemotherapeutic agents. BMC Cancer , 2014. 
15:504. 
5. Rosenthal EL, et al., Phase I dose -escalating trial of Escherichia coli purine nucleoside 
phosphorylase and F -araAMP gene therapy for advanced solid tumors. Ann Oncol , 2015. 
26:1481-7. 
6. Eisenhauer EA, et al ., New response evaluation criteria in solid tumors: Revised RECIST 
guideline (version 1.1). European J Cancer , 2009. 45: 228-247. 
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 66 APPENDICES  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 67 Appendix A: Participant Eligibility Checklist  
A Participant Eligibility Checklist must be completed in its entirety for each subject prior to 
registration.  The completed,  signed, and dated  checklist  must be retained  in the patient’s  study file 
and the study’s Regulatory Binder. 
The study coordinator, treating physician and an independent reviewer must verify that the 
participant’s eligibility is accurate, complete, and legible in source records. A description of the eligibility  verification  process  should be included in the EPIC or  other electronic medical  record 
progress note. 
Protocol Title:  Phase 1/2, Open -label Study Evaluating the Safety of Repeat Administration 
of Ad/PNP -F-araAMP  (Ad/PNP Administered Intratumorally with 
Co-administration of F -araAMP Phosphate Intravenously) in Subjects with 
Recurrent, Local Head and Neck Cancer  
 
  
II. Subject  Information: 
Subject Name/ID:  
Gender:  Male Female  
   
III. Study Information: 
SRC Approved IRB Approved Contract signed 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 68 IV. Inclusion/Exclusion Criteria  
Inclusion Criteria  
(From IRB approved 
protocol)  Yes No Supporting 
Documentation*  
1. Provided Informed Consent     
2. Age ≥ 18 years .    
3. Patients with histologically or cytologically 
confirmed diagnosis of recurrent  cancer of the 
head and neck region for whom there is no 
curative treatment option. For the purposes of 
trial eligibility, cancers of the head and neck 
region shall  include, in addition to head and neck 
squamous cell carcinoma ( HNSCC ), cutaneous 
squamous cell primary sites and squamous cell 
carcinoma of unknown primary presenting with 
neck lymph nodal disease,  as well as 
nasopharyngeal carcinoma  and salivary gland  
tumor s.    
4. All standard or approved treatment options that 
would provide substantive palliation must have  
failed, been exhausted, or patient not eligible for  
them (for example neuropathy, nephropathy, or 
hearing loss precluding the use of cisplatin) .    
5. Tumor mass (primary tumor and/or 
lymphadenopathy) measurable by [CONTACT_44852] ( RECIST ) 
1.1 and technically suitable for intratumoral  
injections (otolaryngologist will determine 
feasibility). Patients with nodal disease (or 
metastatic disease) that is needle accessible are 
eligible. Patients with additional tumors 
(including distant metastatic disease) beyond 
the intratumoral injection accessible tumor(s) 
that are not accessible for intratumoral injection 
are eligible ONLY if t he patient has no other 
treatment option for the metastatic disease and 
treatment of local disease may provide the 
patient some  benefit or palliation.     
6.  Eastern Cooperative Oncology Group  (ECOG ) 
performance status of ≤ 2.    
7.  In the judgment of the Investigator, the patient 
has recovered sufficiently from any previous 
significant therapy side effects or toxicities  prior  
to Ad/PNP administration .    
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 69 Inclusion Criteria  
(From IRB approved 
protocol)  Yes No Supporting 
Documentation*  
8.  Absolute neutrophil count [ANC] ≥ 1,500 
cells/µl; hemoglobin ≥ 9 g/dl, platelets ≥  
100,000/µl.    
9.  Serum creatinine ≤ 1.5 mg/dl, or calculated  
creatinine clearance ≥ 60 ml/min .    
10.  Bilirubin ≤ upper limit normal [ULN], alanine 
aminotransferase [ALT] ≤ 1.[ADDRESS_1136300] and/or 
aspartate aminotransferase [AST] ≤ 1.[ADDRESS_1136301],  
alkaline phosphatase ≤ 2.[ADDRESS_1136302] .    
11.  Prothrombin time (PT)/international 
normalized  ratio (INR) ≤ 1.[ADDRESS_1136303] .    
12.  Activated partial thromboplastin (aPTT) time ≤  
1.[ADDRESS_1136304] a negative urine or 
serum pregnancy at screening (pregnancy test 
is not required for patients with bilateral 
oophorectomy and/or hysterectomy or for those  
patients who are > 1 year postmenopausal)     
14.  All patients of reproductive potential must 
agree  to use a medically acceptable form of  
contraception (e .g., hormonal birth control, 
double -barrier method) or abstinence.     
 
  
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -002 V4.0 06 May 2022  
 
 
 Page 70 Exclusion Criteria  
(From IRB approved 
protocol)  Yes No Supporting 
Documentation*  
1.  Prior history or current diagnosis of leukemia .    
2.  Have received any gene therapy products or  
oncolytic viral therapy .    
3.  Receiving allopurinol .    
4.  Received an investigational drug within [ADDRESS_1136305] injection of Ad/PNP .    
5.  Received radiation treatment < [ADDRESS_1136306] 
injection of Ad/ PNP and  does not have any RECIST 
1.1 evaluable lesions that are outside the radiation 
field. (If the patient has RECIST  1.1 evaluable lesions 
outside the radiation field then they can be included) .    
6.  Received chemotherapy (systemic anticancer 
treatment) < [ADDRESS_1136307] injection of 
Ad/PNP and have not recovered from all the related 
side effects. (If the patient has recovered from all 
related side effects or has reached a new  baseline , 
then they may begin receiving treatment at sooner  
than 4 weeks ).    
7.  Have significant baseline neuropathy (> Grade 2 
based on Common Terminology Criteria for 
Adverse Events [ CTCAE ] v5.0).    
8.  Uncontrolled intercurrent disease (e.g., diabetes,  
hypertension, thyroid disease, active infection) .    
9.  Had within 6 months prior to enrollment: myocardial 
infarction ( MI), cerebral vascular accident (CVA) , 
uncontrolled congestive heart failure (CHF ), 
significant liver disease, unstable angina .    
10.  Fever (temperature > 38.1o C orally) .    
11.  Receiving chronic systemic corticosteroids (> 3 
weeks) or any chronic immunosuppressive 
medications within [ADDRESS_1136308] injection of 
Ad/PNP. Subjects receiving short courses of 
corticosteroids are considered eligible  for the study.     
12.  Receiving anticoagulants other than those to  
maintain patency of venous lines ,    
13.  Women who are pregnant or breast feeding ,    
14.  History of HIV infection. No requirement for  testing.     
* All subject files must include supporting documentation to confirm subject eligibility. The method of 
confirmation can include, but is not limited to, laboratory test results, radiology test results, subject self -report, 
and medical record review.  
 
CONFIDENTIAL  GeoVax, Inc.  
 Ad/PNP -F-araAMP  
Protocol No. PNP -[ADDRESS_1136309] is [ eligible / ineligible ] for 
participation in the study. This study is approved by [CONTACT_115201], the Stanford IRB, and has finalized financial and contractual agreements as required by [CONTACT_114054]’s Research Management Group. 
 
 
Treating Physician Signature:  [CONTACT_1782]:  
Printed Name:  
   
[CONTACT_138690]:  Date:  
Printed Name:  
   
[CONTACT_115211]:  Date:  
Printed Name:  
 